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INTRODUCTION 
 
The recognition of risk factors for coronary heart disease is one of the 
major achievements of coronary heart disease epidemiology in the 20th century. 
Widespread interest in coronary heart disease and its prevention grew from 
the observation of increased rate of fatal and non-fatal myocardial infarction, 
particularly in men of relatively young age in westernized societies during the 
1950s, 1960s and early 1970s.This led to landmark studies, such as the 
Framingham heart study initiated in 1948 and including close to 5000 men and 
women living in town of Framingham, near Boston USA. This cohort study 
together with several other similar studies, has subsequently demonstrated the 
importance of a number of risk factors1. 
A major shift in recent thinking has led to a preference for coronary heart disease 
risk profiling instead of the diagnosis and treatment of individual risk factors such 
as elevated blood pressure and cholesterol. By the year 2020, the burden of 
atherosclerotic coronary heart disease in India will surpass that in other regions of 
the world2.Hence the current study has been undertaken to assess the coronary 
heart disease risk profile and stratify the risk of persons attending the master 
health checkup in our  institution . 
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                                               AIM OF THE STUDY 
1. To evaluate the coronary heart disease risk factors of persons attending 
the MASTER HEALTH CHECKUP CLINIC of Government Stanley 
Hospital. 
2. To evaluate and stratify the risk according to National cholesterol                                                               
education programme-Adult Treatment Panel III(NCEP-ATPIII) 
guidelines. 
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REVIEW OF LITERATURE 
 
EPIDEMIOLOGY: 
   PREVALENCE: 
           Worldwide: 
Cardiovascular disease  accounts for 18 million deaths per year in the 
world, coronary heart disease and cerebrovascular diseases being responsible for 
two thirds of the deaths and for approximately 22% of the 55 million deaths due to 
all causes3.Estimates on mortality due to coronary heart disease according to the 
region indicate that developing countries contribute with a greater part of the 
overall burden of mortality due to the disease than developed countries4,with a 
relative excess of 70%. 
India: 
There have been no large prospective cohort studies to define the incidence 
of coronary heart disease in indians. The prevalence of coronary heart disease is 
rapidly increasing in India and is a major contributor to mortality and morbidity in 
india5,6.Conservative estimates suggest that in 1990 coronary heart disease was 
responsible for 2.39 million deaths and the nation incurred a loss of 28.59 million 
disabilty adjusted life years(DALY’s)7.Epidemiological transition, with increasing 
life expectancy and demographic shifts of population ,age profile, combined with 
lifestyle related increases in the levels of coronary heart disease risk factors is 
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accelerating the coronary heart disease epidemic in india8.Recently,the prevalence 
of coronary heart disease in an urban population in South India was reported to be 
11%9. 
Immigrant Indians: 
Indian immigrants in industrialized nations have higher prevalence rates 
compared to native indians. They are presumably at a more advanced 
epidemiologic transition. The first report to highlight the high coronary heart 
disease prevalence among immigrant indians came from an autopsy study from 
singapore. Coronary heart disease with myocardial infarction was 7 times more 
common in indians compared to chinese men10.Other studies from 
uganda11,singapore12,south africa13and fiji14,confirmed a three fold higher coronary 
heart disease prevalence in indians compared to the respective natives.  
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      CORONARY HEART DISEASE RISK FACTORS 
Considerable work has gone into the epidemiology, pathophysiology and 
clinical implications of coronary heart disease risk factors, and many risk  factors 
have been associated with a incidence of coronary heart disease. Furthermore, 
these risk factors can be divided into ‘modifiable’or ‘non-modifiable’ depending 
upon the extent to which they can be altered or not. 
MAJOR RISK FACTORS: 
1.Modifiable: 
   a.Hypertension 
   b.Dyslipidemia 
   c.Diabetes Mellitus 
   d.Smoking 
   e.Lifestyle factors such as diet, obesity. physical inactivity. 
2.Non-modifiable: 
  a.Family history of CHD 
  b.Personal history of CHD 
  c.Low birth weight 
  d.Increasing age 
  e.Male sex 
  f.Ethnic origin 
  g.Familial hyperlipidemia . 
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Emerging lipid risk factors: 
 a.Elevated triglycerides 
 b.Lipoprotein remnants 
 c.Lipoprotein(a) 
 d.Small dense LDL 
 e.Apolipoproteins: elevated ApoB , low ApoA1  
Emerging non-lipid risk factors: 
 a.Homocysteine 
 b.Thrombogenic/                         High fibrinogen,activated factor VII, 
 hemostatic factors;                      Plasminogen activator inhibitor(PAI-1)                                  
                          
The important ‘modifiable’ risk factors, which are well documented, 
include smoking, diabetes mellitus, hypertension and dyslipidemia. Male sex, 
family history and increasing age are the principal ‘non-modifiable’ major risk 
factors. 
HYPERTENSION: 
The Framingham study1 was the first study to show conclusively that high 
blood pressure increased the risk of coronary heart disease. Indeed, there almost 
appears to be a “dose-response” relationship between hypertension and the risk of 
stroke or coronary heart disease, in that the higher the blood pressure, the greater 
the risk; conversely the reduction of blood pressure by anti-hypertensive treatment 
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reduces the risk of stroke and myocardial infarction. Other studies have since 
confirmed that the increased risk of coronary heart disease extends across racial, 
gender and age categories. Coronary heart disease also frequently co-exists with 
other risk factors, such as diabetes mellitus, hyperlipidemia. Furthermore, 
hypertensive patients have a worse prognosis after myocardial infarction than 
normotensive  patients or those treated for hypertension15 
DYSLIPIDEMIA 
Raised total plasma cholesterol levels together with elevated low density 
lipoproteins(LDL) and lowered high density lipoprotens (HDL) cholesterol levels 
are associated with a high risk of  atherosclerosis and increased risk of coronary 
heart disease risk16,17,18.Atherogenic dyslipidemia ; elevated triglycerides, small 
dense LDL and low HDL occurs commonly in persons with premature CHD19 
Many studies have also shown that reducing cholesterol by 
pharmacological means reduces the risk of eventual coronary heart disease both as 
primary and secondary prevention20,21 
DIABETES MELLITUS: 
 Diabetes mellitus another well established risk factor for coronary heart 
disease. Indeed , macro and microvascular complications along with increased 
atherosclerosis are well documented with diabetes mellitus22,23,24.In particular, 
diabetics have almost a 50% higher chance of developing coronary heart disease 
than non-diabetics. It is all the more important as diabetes often co-exists with 
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other risk factors, such as hyperlipidemia and hypertension.Other coexisting 
features such as hyperinsulinemia and insulin resistance have also been implicated 
pathophysiologically in coronary heart disease. Recently , studies such as the 
UKPDS25,have shown that strict control  of blood sugar resulted in lower 
incidence of coronary heart disease 
SMOKING: 
Smoking continues to be one of the most important major modifiable risk 
factors in the development of coronary heart disease 26.Smokers have been shown 
to have almost a twofold increase in the risk of coronary heart disease as compared 
to non-smokers27,whilst smokers who stop smoking lower their risk of  coronary 
heart disease to that in non-smokers, but the risk reduction may take 2 years.. 
Cigarette smoking has been shown to have adverse effects on the lipid 
profile(it lowers HDL, but increases LDL and triglycerides) as well as causing an 
acute increase in blood pressure levels28,29,30,31.Cigarette smoking also adversely 
affects platelet function and coagulation parameters, increasing the risk of 
thrombosis. 
OBESITY: 
The precise role of obesity as an independent coronary heart disease  risk 
factor remains unclear. The definition of obesity is arbitrary but is often defined as 
an increase of 20% above ideal body weight. Obesity has a direct relationship with 
all the risk factors except smoking. Indeed obesity influences the other risk factors 
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such as dyslipidemia, hypertension and diabetes and thereby increases coronary 
heart disease risk.32,33.  It has also been shown that patients with a ‘central’ fat 
distribution tend to be at a higher risk as opposed to a generalized obesity34,35 
FAMILY HISTORY: 
Epidemiological studies have shown that diseases such as diabetes, 
hypertension, obesity and some forms of hypercholesterolemia have a familial 
predilection. These would put the individual at a higher risk of coronary heart 
disease .Other than certain familial forms of dyslipidemias , no familial forms of 
cardiovascular disease have been described. 
AGE: 
Increasing age has been shown to be a risk factor for coronary heart 
disease. The Framingham data1have shown a twofold increase in the rates of 
coronary heart disease in patients over the age of 60.However,this could also be 
due in part to the increased incidence of other coronary heart disease risk factors 
with increasing age.    
MALE SEX: 
Men are more prone to coronary heart disease than women1.It is likely that 
oestrogens may play a protective role in women36,as it is postmenopausal women 
who tend to have incidence rates of coronary heart disease approaching those of 
men37.Similarly,epidemiological data suggest that women who are on hormone 
replacement therapy(HRT) tend to have rates similar to those of premenopausal 
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women38.However the role of HRT in secondary prevention of coronary heart 
disease is debatable. 
ETHNICITY: 
Wide differences exist between the different races with regard to incidence 
of coronary heart disease. The prevalence of coronary heart disease rates in India 
is four fold higher than in the U.S39.The high rates of coronary heart disease in 
India are in sharp contrast to low rates of coronary heart disease in china, 
hongkong, japan, taiwan, malaysia, indonesia, korea  and other asian countries40 
Asian indians have a lower prevalence of conventional risk factors with the 
exception of abnormalities of glucose metabolism.In general, despite having some 
of the highest rates of hypertension and cigarette smoking in the world, coronary 
heart disease rates are low in other asian countries, where stroke is the dominant 
form of cardiovascular disease. Despite high rates of obesity, diabetes mellitus and 
low socioeconomic status, coronary artery disease rates are lower in hispanics  
than white  americans. African  americans have a higher prevalence of  risk 
factors, especially low socioeconomic status, obesity, diabetes, and malignant 
hypertension, and yet they have no higher incidence of coronary artery disease 
than in whites. 
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CARDINAL FEATURES OF CORONARY ARTERY DISEASE IN                
INDIANS 41: 
(a) Greater Prematurity 
(b)  Greater Severity 
(c)  Higher prevalence of insulin resistance syndrome 
(d) lower prevalence of conventional risk factors; hypertension, 
obesity, smoking, serum cholesterol levels(similar to whites but 
higher than other asians) 
(e) Higher prevalence of new and emerging risk factors;  elevated 
lipoprotein(a) homocysteine,  plasma fibrinogen 
 
 PHYSICAL INACTIVITY: 
        Physical  inactivity is an exceptionally common modifiable risk factor for 
coronary artery disease. The risk of coronary artery disease in physically inactive 
people is almost twice that of physically active people42and regular physical 
activity may protect against death from coronary artery disease. 
 DIET: 
       Food intake of  different populations can greatly modify the risk factors and 
can account for some of the differences in coronary  artery disease incidence seen 
among different ethnic groups43.In the GISSI-Prevenzione study44,a mediterranian 
diet along with supplementation with polyunsaturated fats(as 
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omega3polyunsaturated fatty acids)resulted in a significant decrease in coronary 
heart disease events post myocardial infarction. 
 PSYCHOSOCIAL AND BEHVIOURAL FACTORS: 
     Studies have consistently shown that emotional distress precedes the 
development of the symptoms of coronary heart disease45,46,47 
 One large prospective study from Hawaii48involving more than 8000 men failed 
to show any significant correlation between coronary heart disease risk and 
psychosocial/ behavioural  factors. 
           CLUSTERING OF CORONARY HEART DISEASE RISK FACTORS  
                                 THE METABOLIC SYNDROME   
   The metabolic syndrome is a constellation of interrelated risk factors of 
metabolic origin that appear to directly promote the development of 
atherosclerotic coronary heart disease 49.Patients with metabolic syndrome are also 
at increased risk for developing type2 diabetes mellitus. 
  The predominant underlying risk factors  for the syndrome appear to be 
abdominal obesity50,51,52 and insulin resistance 53,54 other associated conditions can 
be physical inactivity 51,55aging56and hormonal imbalance57 
 CLINICAL DIAGNOSIS OF METABOLIC SYNDROME:                                                                                                                                                                                                                                                                                           
  For the purpose of identification and treatment several organizations have 
attempted to define the metabolic syndrome.In 2001 U.S National cholesterol 
education programme-Adult Treatment Panel III(henceforth called ATP III) 
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recommended that atleast three of the following components are required to 
confirm the diagnosis of metabolic syndrome-abdominal obesity (men≥102cm, 
women≥88cm), increased triglycerides (≥150mg/dl), decreased HDL cholesterol 
(<40mg/dlmen, <50mg/dlwomen), hypertension(≥130/85mmHg) and impaired 
fasting glucose(≥110mg/dl)49 The recent American Heart Association / National 
Heart,Lung,Brain Institute (henceforth called AHA/NHLBI) scientific statement 
on the diagnosis and management of metabolic syndrome has made the following 
modifications to the ATPIII Criteria58 
   
            Risk factor                                Defining level                                                             
Abdominal obesity                             Men≥90cm,women≥80cm 
Elevated triglycerides                         ≥150mg/dl or on drug treatment for elevated 
                                                   Triglycerides                                                
Reduced HDL-C                                 <40mg/dl men,<50mg/dl women or on drug 
                                                  Treatment for reduced HDL-C                   
Elevated blood pressure                  ≥130 / 85 or on anti-hypertensive treatment   
Elevated fasting glucose                     ≥100mg/dl or on drug treatment for elevated 
                                                   glucose         
A series of studies 59-69have found that many middle-aged people with the 
metabolic syndrome are at increased absolute risk for atherosclerotic coronary 
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heart disease in the near future. In the Botnia study59an almost threefold increased 
risk of coronary heart disease was found in those subjects with the metabolic 
syndrome,compared to those without. 
Physical activity and a healthy, low-fat diet are associated with low levels 
of all risk factors associated with the metabolic syndrome and in patients with 
diabetes mellitus.                        
                    CONCEPT OF GLOBAL RISK 
The term risk factor refers to characteristics that are independently related 
to the risk of subsequent occurrence of coronary heart disease. From the large 
prospective epidemiological studies such as the Framingham study, the multiple 
risk factor intervention trial(MRFIT) and the Munster Heart study(PROCAM),it is 
known that a person’s risk of developing coronary heart disease rarely depends on 
a single risk factor 70-72.In most cases, the risk is determined by the interaction of 
two or more risk factors, each often of only mild degree.It is important to realize 
that the combined risk conferred by multiple risk factors may be considerably 
greater than the sum of the individual risks and their joint effect on global risk 
may be marked. The absolute risk of an individual determines future risk for 
symptomatic events and sets the indication for action 
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GLOBAL RISK ASSESSMENT: 
In the light of increasing prevalence of coronary artery disease among 
indians, it is of vital importance to develop specific algorithms to evaluate the 
global risk of coronary artery disease in all individuals considered to be at risk.At 
present, there are no specific established guidelines that are widely accepted for 
calculating the risk of coronary heart disease(CHD) in indians. In the absence of 
such guidelines, it would be prudent to adopt the guidelines by the Adult 
Treatment Panel III(ATPIII) based on Framingham Risk Score method49 
ESTIMATING 10-YEAR CHD RISK FOR MEN AND WOMEN 
Risk assessment for determining the 10-year risk for developing coronary 
heart disease may be carried out using Framingham risk scoring. The risk status in 
persons without clinically manifest coronary heart disease(CHD) or other clinical 
forms of atherosclerotic disease is determined by a two step procedure. First, the 
number of risk factors modifying LDL goal is counted49         
                      RISK FACTORS MODIFYING LDL GOALS 
   CIGARETTE SMOKING 
   HYPERTENSION(BP≥140/90mm Hg or on anti-hypertensive medication) 
    LOW HDL CHOLESTEROL(<40mg/dl)* 
    Family H/o Premature CHD(first degree relative men≤55,women≤65) 
     AGE(men≥45,women≥55) 
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*HDL>60mg/dl counts as a ‘negative’ risk factor;its presence removes 1 
risk factor from the total count.    
Second, for persons with multiple(2+) risk factors,10 year risk assessment 
is carried out with Framingham scoring as shown in Annexure 1,2. 
Risk factors used in Framingham scoring include age ,total cholesterol, 
HDL cholesterol, blood pressure and cigarette smoking.                                                                                                                                                                                        
                              RISK  STRATIFICATION 
ATP III identifies three categories of risk for CHD that modify goals 49and 
 
 modalities of LDL-lowering therapy: established CHD and CHD risk equivalents, 
 
 multiple (2+) risk factors, and 0–1 risk factor 
 
(a). Identification of persons with CHD and CHD risk equivalents 
 
Coronary heart disease:. Persons with CHD are at very high risk for future CHD  
 
events (10-year risk >20 per-cent). Several clinical patterns constitute a diagnosis 
 
 of CHD; these include history of acute myocardial infarction, evidence of silent  
 
myocardial infarction or myocardial ischemia, history of unstable angina and  
 
stable angina pectoris, and history of coronary procedures (coronary angioplasty  
 
and coronary artery surgery) 
 
Other clinical atherosclerotic diseases: Persons in this subcategory have a CHD  
 
risk equivalent. Included are those with peripheral arterial disease, abdominal  
 
aortic aneurysm, carotid artery disease (symptomatic) [e.g., transient ischemic  
 
attack or stroke of carotid origin] or >50 percent stenosis on angiography or  
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ultrasound), and likely other forms of clinical atherosclerotic disease (e.g., renal  
 
artery disease). 
 
Diabetes mellitus:. ATP III counts diabetes as a CHD risk equivalent.  
 
 
Multiple risk factors and 10-year risk for CHD >20 percent: 
 
Based on 10-year risk assessment using Framingham scoring, a person 
 
 in this category can be said to have a CHD risk equivalent. 
       
(b)MULTIPLE( 2 0R MORE) RISK FACTORS: 
 
Individuals who fall into the multiple (2or more)risk factor category may be  
 
further subclassified according to their 10-year CHD risk using the Framingham  
 
scoring system  into those with 10-year CHD risk of more than 20 percent,10 to 20  
 
percent.and less than 10 percent.This further identifies individuals whose 10-year  
 
risk may warrant intensive management despite having a milder risk factor profile 
 
 and allows better  targeting of treatments to those who will benefit most.  
 
(c). Zero to one risk factor: 
 
Most persons with 0–1 risk factor have a 10-year risk <10 percent.   
 
                                                        
                                  RISK    MANAGEMENT 
 
 SMOKING: 
    
    Efforts to achieve smoking cessation by physicians are worthwhile. Aggressive  
 
Urging by physicians will convince some individuals to quit smoking. 
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 DIETARY CHANGES: 
 
  Dietary changes have been found to be important in the management of diabetes  
 
and hypertension, as well as in treating obesity. Indeed, diets which are higher in  
 
fresh fruits and vegetables,73fish,74fibre and whole grains are associated with  
 
lower rates of heart disease. 
 
 OBESITY: 
 
 It has been shown that even modest(5-10%) reductions in weight are associated  
 
with health benefits, with reductions in blood pressure and cholesterol and  
 
triglyceride levels75.Reduction of waist circumference results in improvement of  
 
metabolic coronary heart disease risk factors(blood pressure , lipid and glucose  
 
levels),but this is probably dependent on the loss of body weight76.A calorie  
 
restricted lipid-lowering diet is the central component in weight reduction.Suitable  
 
regular physical activity adapted to the individual fitness and health status helps in  
 
weight reduction and in the maintenance of reduced body weight. 
 
PHYSICAL INACTIVITY: 
 
 Physical inactivity is an exceptionally common modifiable risk factor for  
 
Coronary artery disease.Regular aerobic physical activity has favourable effects on  
 
body weight,blood pressure,plasma lipids,glucose tolerance,and insulin sensitivity  
 
and may also have a direct protective effect against the triggering of acute cardiac  
 
events.The duration of physical activity should preferably be 30-40 min, including  
 
a 5-10 minute warm-up phase before the 20-30min aerobic phase and a 5-10 min 
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Cool-down phase at its end, and as frequent as 4-5 times weekly. 
 
HYPERTENSION: 
 
  Several lifestyle interventions are known to have a blood pressure-lowering  
 
Effect. Treatment based on these interventions alone may be sufficient for patients  
 
With mildly elevated blood pressure and as emphasized above, it should always be  
 
advised for patients who are receiving anti-hypertensive drugs, because the dosage  
 
of anti-hypertensive drug needed for good blood pressure control can be reduced  
 
by lifestyle measures. Lifestyle interventions include:  weight  reduction   in  
 
overweight  individuals; reduction in use of sodium chloride to less than 5g/day;  
 
restriction of alcohol consumption to no more than 10-30g/day and to no more  
 
than 10-20g/day in women; and regular physical activity in sedentary individuals.  
 
   Efforts should be made to help hypertensive smokers to stop smoking. 
 
   Randomized trials of antihypertensive treatment have demonstrated the benefits  
 
   Of lowering blood pressure by antihypertensive drugs77,78.Evidence from  
 
placebo-controlled and comparative trials also makes it clear that coronary heart  
 
disease protection can be obtained by treatments based on a variety of  
 
antihypertensive  Drug classes ,ie;diuretics, beta-blockers,ACE inhibitors,Calcium  
 
antagonists andAngiotensinII antagonists.This presumably means that protection is  
 
due to a Substantial degree ,to blood pressure lowering per se 79,80 
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DYSLIPIDEMIA: 
 
   Lipid lowering can be undertaken both by pharmacological and non- 
 
pharmacological  means. Exercise, high fibre  diet, calorie reduction and better  
 
diabetic control help in lowering lipid levels. Both secondary prevention  
 
trials 81-84and primary prevention trials 85-87 have shown unequivocally the  
 
benefits derived from lowering cholesterol,with a 1% reduction in serum  
 
cholesterol being associated with a 2% reduction in coronary heart disease, whilst  
 
a 1% increase in HDL is associated with a 2-4% reduction in coronary heart  
 
disease. Effective lipid Lowering can also slow the rate of progression of coronary  
 
heart disease and also Achieve regression of atherosclerosis within 2 years. 
    
         The basic principle that guides cholesterol-lowering intervention is that the  
 
intensity of treatment is directly related to the degree of risk for CHD events. Both 
 
short-term (10-year) risk and long-term risk must be considered for treatment  
 
decisions. Persons with existing CHD (or a CHD risk equivalent) are at the highest 
 
risk; for this reason, they have the lowest goal level for LDL cholesterol and  
 
receive the most intensive treatment.For persons without CHD, classification and 
 
treatment goals are based on the category of risk, of which there are two—multiple  
 
(2+) risk factors other than LDL, and 0–1 risk factor. Persons with 2+ riskfactors 
 
 have an LDL goal that is not quite as low as that for persons with CHD (or CHD  
 
risk equivalents)ATP III49 differs from ATP II in that it distinguishes three  
 
subcategories of risk among persons with multiple (2+)risk factors: 10-year risk  
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for hard CHD >20 percent,10–20 percent, and <10 percent. Among the group 
 
with multiple risk factors, those at highest risk receive the most intensive LDL- 
 
lowering therapy, and those with the lowest risk receive the least intensive therapy 
. 
For persons with 0–1 risk factor, LDL goal levels are not as low as for persons  
 
with multiple risk factors, and intensive LDL-lowering therapy is not required 
 
unless LDL cholesterol levels are very high 
 
Therapeutic goals for LDL cholesterol 
 
ATP III49 recommends that LDL cholesterol be the primary target of therapy. The  
 
LDL cholesterol goals for each risk category are shown in Table 1. 
                                                   TABLE 1 
                RISK LEVEL               LDL-C GOAL 
 
CHD and CHD risk equivalent 
 
Multiple(2+) risk factors 
 
 0-1 risk factor 
 
 
   <100mg/dl 
 
    <130mg/dl* 
 
     < 160mg/dl 
 * LDL-C goal for multiple-risk-factor persons with 10-year risk >20 percent  is  
 
    <100 mg/dl 
 
Persons with CHD or CHD risk equivalent have an LDL cholesterol goal of <100  
 
mg/dL. Those with multiple risk factors have an LDL cholesterol goal of <130 
 
mg/dL; an exception is the patient with a CHD risk equivalent (>20 percent per 10   
 
years) who has an LDL cholesterol goal <100 mg/dL. Finally, those with 0–1 
 
risk factor have a goal LDL cholesterol of <160 mg/dL.These goals are set to  
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maximize reduction in both short-term and long-term risk.For persons whose LDL  
 
cholesterol levels are above the goal for the category, the goal of therapy is  
 
achieved through the judicious use of lifestyle and drug therapies.Lifestyle therapy  
 
in clinical management is designated.Therapeutic Lifestyle Changes (TLC). TLC 
 
includes the following: (a) reduced intakes of saturated fats and cholesterol,  
 
(b)therapeutic dietary options to enhance LDL lowering (plant stanols/sterols and 
 
increased viscous fiber), (c) weight control, and (d)increased physical activity.  
 
                ATP III 49recommends a two-step approach to cholesterol management 
 
 Priority goes to attaining the goal for LDL cholesterol; thereafter emphasis shifts 
 
 to management of the metabolic syndrome and other lipid risk factors.Once the 
 
 lipoprotein analysis is evaluated, risk factor counting and, if necessary,10-year  
 
risk assessment are carried out to determine risk status. The patient is then started  
 
on dietary therapy or discharged with instructions for appropriate life-habit 
 
modifications. If the patient has CHD or a CHD risk equivalent, LDL-lowering  
 
drug therapy can be started simultaneously with dietary therapy if the LDL 
 
level warrants.After an appropriate trial of dietary therapy to reduce LDL  
 
cholesterol (~ 3 months), two additional therapeutic decisions may be required.  
 
First, if the LDL cholesterol goal has not been achieved, consideration may 
 
be given to initiating drug therapy. Second, if the metabolic syndrome is present,  
 
additional lifestyle changes (i.e., weight reduction and increased physical activity) 
 
will be needed. Later, if lifestyle therapies do not alleviate the metabolic  
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syndrome, drug therapy for treatment of the metabolic risk factors may be  
 
required. 
 
  Management of LDL Cholesterol 
 
The following summarizes the ATP III 49 approach to management of persons in  
 
the three categories of risk. 
 
a. CHD and CHD risk equivalents 
 
For persons with CHD and CHD risk equivalents, the type and intensity of LDL- 
 
lowering therapy are adjusted according to baseline LDL cholesterol level, i.e., 
 
whether≥130 mg/dL, 100–129 mg/dL, or <100 mg/dL. Each subcategory of 
 
LDL cholesterol is discussed below. 
 
1) Baseline LDL cholesterol ≥130 mg/dL: 
 
Persons with LDL cholesterol ≥130 mg/dL generally will require an LDL- 
 
lowering drug to achieve LDL cholesterol <100 mg/dL. Therefore, a cholesterol- 
 
lowering drug should be initiated simultaneously with TLC and maximal control  
 
of other risk factors. If the LDL cholesterol falls to the range of 100–129 mg/dL  
 
on cholesterol-lowering therapy, several options are available depending on  
 
circumstances;(1)LDL lowering can be intensified with dietary therapy to achieve  
 
an LDL cholesterol level <100 mg/dL(2) .LDL lowering can be intensified with  
 
drug therapy to achieve an LDL cholesterol level <100 mg/dL..If the on-treatment  
 
LDL cholesterol level is near the goal of therapy, the physician can maintain 
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the current LDL-lowering therapy unchanged..If the metabolic syndrome is  
 
present, dietary therapy is intensified by increased efforts to reduce excess weight  
 
and increase physical activity..If the patient has elevated triglycerides or low 
 
HDL, a different lipid-lowering drug can be considered (e.g., nicotinic acid or  
 
fibric acid) for combination therapy with an LDL-lowering drug(statin) 
 
2) Baseline LDL cholesterol 100–129 mg/dL: 
 
   When baseline LDL cholesterol is 100–129 mg/dL, several therapeutic options  
 
likewise are available. All approaches include TLC as initial therapy. Depending 
 
on circumstances, the following options are available: Inclusion of therapeutic  
 
dietary options (e.g., plant stanol /sterols and increased viscous fiber) can help to  
 
achieve the LDL goal..If LDL cholesterol levels remain appreciably above 100  
 
mg/dL after 3 months of maximal dietary therapy, consideration can be given to 
 
adding an LDL-lowering drug..If the patient has an elevated triglyceride or low 
 
HDL cholesterol level, another lipid-lowering drug can be considered (e.g.,  
 
nicotinic acid or fibric acid)..If the LDL cholesterol level falls to near the goal on  
 
dietary therapy alone, the physician can choose to forgo use of a lipid-lowering  
 
drug for the present.Because other risk factors may have contributed importantly 
 
to development of CHD in persons with low LDL levels, maximal control of  
 
nonlipid risk factors is necessary. 
 
3) Baseline LDL cholesterol <100 mg/dL 
 
If baseline LDL cholesterol is below the goal of therapy, further LDL-lowering  
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therapy is not currently recommended. Emphasis should be placed on controlling 
 
other risk factors and the metabolic syndrome.The TLC diet should be  
 
recommended to the person to help maintain a low LDL. 
 
                                                    TABLE 2 
Subcategory of 
LDL cholesterol 
level 
LDL cholesterol 
goal 
Level at which to 
initiate therapeutic 
lifestyle 
change(TLC) 
Level at which to 
initiate LDL-
lowering drugs 
 
≥130mg/dl 
 
<100mg/dl 
>100mg/dl Start drug therapy 
simultaneously 
with dietary 
therapy 
 
100-129mg/dl 
 
<100mg/dl 
 
>100mg/dl 
Consider drug 
options* 
 
<100mg/dl 
 
 
<100mg/dl 
TLC and 
emphasize weight 
control and 
physical activity 
LDL-lowering 
drugs not required 
 
* Some authorities recommend use of LDL-lowering drugs in this category if an  
 
LDL cholesterol <100 mg/dL cannot be achieved by TLC. Others prefer use of  
 
drugs that primarily modify other lipoprotein fractions, e.g., nicotinic acid and  
 
fibrate. Clinical judgment also may call for withholding drug therapy in this  
 
subcategory. 
 
 
b. Multiple (2+) risk factors: 
 
ATP III distinguishes three subcategories of risk among persons with multiple risk 
 
 factors, depending on 10-year risk: >20 percent, 10–20 percent, and <10 percent.  
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Within this category of multiple (2+) risk factors, intensity of therapy is adjusted 
 
 according to 10-year risk and LDL cholesterol level.The treatment approach for  
 
each subcategory is shown in Table 3 . 
 
The following reviews the approach to each subcategory in more detail. 
 
1) Multiple risk factors, and 10-year risk >20 percent: 
 
Persons with multiple risk factors and 10-year risk >20 percent have a CHD risk  
 
equivalent and are treated as described in the previous section . 
 
2) Multiple risk factors, and 10-year risk 10–20 percent: 
 
The goal for LDL cholesterol in this risk category is <130 mg/dL. The therapeutic  
 
aim is to reduce short-term risk as well as long-term risk for CHD. If baseline 
 
LDL cholesterol is ≥130 mg/dL, persons are started on TLC for a 3-month trial of  
 
dietary therapy, possibly augmented by options for further LDL lowering (plant 
 
stanols /sterols and increased viscous fiber). After 6 weeks and again after three  
 
months of dietary therapy, lipoprotein analysis is repeated. If LDL remains ≥130  
 
mg/dL after three months, consideration can be given to starting an LDL-lowering  
 
drug to achieve the LDL goal <130 mg/dL. Should the LDL be less than 130  
 
mg/dL on dietary therapy alone, it can be continued without adding drug  
 
treatment. If the metabolic syndrome is present, more attention should be given 
 
to weight control and increased physical activity.  
 
3) Multiple risk factors, 10-year risk <10 percent: 
 
The goal for LDL cholesterol in this risk category like-wise is <130 mg/dL. The  
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therapeutic aim, however, is primarily to reduce longer-term risk. If baseline LDL 
 
cholesterol is ≥130 mg/dL, persons are started on dietary therapy for reducing  
 
LDL cholesterol. Options for enhancing LDL lowering can be employed if needed 
 
to achieve the goal of therapy. After three months of dietary therapy, lipoprotein  
 
analysis is repeated. If LDL is <160 mg/dL on dietary therapy alone, the dietary 
 
therapy should be continued. LDL-lowering drugs generally are not recommended  
 
because the patient is not at high short-term risk. On the other hand, if LDL cho- 
 
lesterol is ≥160 mg/dL, drug therapy can be considered to achieve an LDL  
 
cholesterol <130 mg/dL.  
                                   
                                                TABLE 3 
 
10 year risk 
 
LDL cholesterol 
Goal 
Level at which to 
initiate therapeutic 
lifestyle 
change(TLC) 
Level at which to 
initiate LDL-
lowering drugs 
 
>20% 
 
<100mg/dl 
≥100mg/dl Treat as CHD 
equivalent 
 
10-20% 
 
<130mg/dl 
 
≥130mg/dl 
 
≥130mg/dl 
 
<10% 
 
 
<130mg/dl 
 
≥130mg/dl 
 
≥160mg/dl 
 
c. Zero to one risk factor: 
 
Most persons with 0–1 risk factor have a 10-year risk <10 percent. The goal for  
 
LDL cholesterol in this risk category is <160 mg/dL. The primary aim of therapy  
 
is to reduce long-term risk. When baseline LDL cholesterol is ≥160 mg/dL,  
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persons are started on dietary therapy for three months. After 6 weeks, the LDL  
 
response is evaluated and dietary enhancers of LDL lowering (plant stanols/sterols  
 
and increased viscous fiber) may be added if necessary to reach the LDL goal.  
 
After 3 months, lipoprotein analysis is repeated. If LDL cholesterol is <160  
 
mg/dL, dietary therapy is continued. For LDL cholesterol 160–189 mg/dL, drug  
 
therapy is optional depending on clinical judgment. Factors that favor use of drugs  
 
in this category include:A severe single risk factor (heavy cigarette smoking,  
 
poorly controlled hypertension, strong family history of premature CHD, or very  
 
low HDL cholesterol)..Multiple life-habit risk factors , emerging risk factors (if  
 
measured),10-year risk approaching 10 percent (if measured). If LDL cholesterol  
 
is≥190 mg/dL despite dietary therapy in persons with 0–1 risk factor, drug  
 
therapy can be considered to achieve the goal of therapy in all adults. For persons  
 
with severe elevations of LDL cholesterol (e.g., ≥220 mg/dL), drug therapy can be  
 
started together with dietary therapy. Most such patients will have genetic forms  
 
of hypercholesterolemia that cannot be adequately treated with dietary therapy  
 
alone.                                                 
                                                 TABLE 4 
 
Risk category 
 
LDL cholesterol 
Goal 
Level at which to 
initiate therapeutic 
lifestyle 
change(TLC) 
Level at which to 
initiate LDL-
lowering drugs 
 
0-1 risk factor* 
 
<160mg/dl 
 
≥160mg/dl 
 
≥190 mg/dl 
*Most persons with 0-1 risk factor have a 10-year risk of CHD <10% 
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d. Management of LDL cholesterol when risk assessment 
 
begins with Framingham scoring : 
 
If clinicians choose to begin risk assessment with Framingham risk scoring, the  
 
treatment algorithm is similar to that beginning with risk factor counting. The 
 
only difference occurs for persons whose 10-year risk is 10–20 percent and who  
 
have 0–1 risk factor; if one begins with risk factor counting, such persons would 
 
not have their 10-year risk calculated. This difference occurs in only 2.6 percent of  
 
the U.S. population that has 0–1 risk factor.                                             
                                                    
                                                     TABLE 5 
 
10 year CHD risk 
 
LDL 
cholesterol 
goal 
Level at which to 
initiate therapeutic 
lifestyle 
change(TLC) 
Level at which to 
initiate LDL-
lowering drugs 
 
>20%(High risk) 
 
<100mg/dl 
≥100mg/dl Treat as CHD 
equivalent 
 
10-20%(2+ risk factors)-
moderately high risk 
 
<130mg/dl 
 
≥130mg/dl 
 
≥130mg/dl 
<10%(2+ risk             
factors)-moderate risk 
 
<130mg/dl 
 
≥130mg/dl 
 
≥160mg/dl 
<10%(0-1 risk factor)-
low risk 
<160mg/dl ≥160mg/dl ≥190mg/dl 
 
e. Recommendations for persons whose LDL cholesterol levels are below goal 
 
For persons whose LDL cholesterol levels are already below goal levels upon  
 
encounter, instructions for appropriate changes in life habits, periodic follow-up, 
 
and control of other risk factors are required .For all persons without CHD or  
 
CHD risk equivalents whose LDL is below goal, the diet for the general public  
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and a physical activity regimen should be recommended. For those with CHD or  
 
CHD risk equivalent,the therapeutic diet (TLC diet) should be recommended even  
 
if the LDL is below goal. Follow-up lipoprotein analysis should be carried out . 
 
Management of atherogenic dyslipidemia and the metabolic syndrome: 
 
After an adequate trial of dietary therapy for LDL lowering, attention should turn  
 
to atherogenic dyslipidemia and the metabolic syndrome. Treatment of these 
 
conditions usually begins after an initial 3-month period of dietary therapy to  
 
lower LDL cholesterol.Therapy for atherogenic dyslipidemia and metabolic syn- 
 
drome thus begins after the LDL goal has been achieved with TLC alone or  
 
simultaneously with initiation of more intensive LDL-lowering therapy with  
 
drugs. 
 
a. Atherogenic dyslipidemia 
 
For atherogenic dyslipidemia,  treatment strategy focuses on triglycerides. If  
 
triglycerides are ≥150 mg/dL and HDL cholesterol is <40 mg/dL, a diagnosis of 
 
atherogenic dyslipidemia is made. The patient likely has the metabolic syndrome  
 
if triglycerides are ≤200 mg/dL, and specific drug therapy to reduce triglyceride- 
 
rich lipoproteins (TGRLP) is not indicated. However,  if the patient has CHD or  
 
CHD risk equivalents,  consideration can be given to using a drug to 
 
raise HDL cholesterol (fibrate or nicotinic acid), as outlined above under LDL- 
 
lowering therapy. On the other hand, if triglycerides are 200–499 mg/dL, 
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non-HDL cholesterol(T.C-HDL) becomes a secondary target of therapy. Goals for  
 
non-HDL cholesterol are 30 mg/dL higher than those for LDL cholesterol. First  
 
the LDL cholesterol goal is attained, and if non-HDL remains elevated, additional  
 
therapy may be required to achieve the non-HDL goal. Alternative approaches for  
 
treatment of elevated non-HDL cholesterol that persists after the LDL goal has  
 
been achieved are (a) higher doses of statins, or (b) moderate doses of statins + 
 
triglyceride-lowering drug (nicotinic acid or fibrate). If triglycerides are very high 
 
(500 mg/dL), attention turns first to prevention of acute pancreatitis, which is more  
 
likely to occur when triglycerides are ≥1000 mg/dL. Triglyceride-lowering 
 
drugs (fibrate or nicotinic acid) become first line therapy; although statins can be  
 
used to lower LDL cholesterol to reach the LDL goal, in these patients it is often  
 
difficult (and unnecessary) to achieve a non-HDL cholesterol goal of only 30  
 
mg/dL higher than for LDL cholesterol. 
 
b. Metabolic syndrome 
 
Beyond treatment of elevated triglycerides, with drugs if necessary, first-line  
 
therapy for the metabolic syndrome is change in life habits, especially reducing 
 
weight and increasing physical activity. The approach to treatment of the  
 
metabolic syndrome with life-habit modification is presented below. 
 
Management of the metabolic syndrome through life habit changes 
 
a. Weight control 
 
In ATP III49, emphasis on weight reduction is delayed until after other dietary  
 32
 
measures are introduced for LDL lowering (reduced intakes of saturated fatty  
 
acids and cholesterol and possibly other options for LDL lowering [plant  
 
stanols/sterols and increased dietary fiber]) . The delay in emphasizing weight  
 
reduction is to avoid overloading new patients with a multitude of dietary  
 
messages and to concentrate first on LDL reduction. After an adequate trial of  
 
LDL-lowering measures, attention turns to other lipid risk factors and the  
 
metabolic syndrome . Weight reduction then becomes a major focus of  
 
TLC.Indeed, weight control alone, in addition to lowering LDL cholesterol,  
 
favorably influences all of the risk factors of the metabolic syndrome. 
 
b. Increased regular physical activity 
 
 The recommendation for increased physical activity is introduced when TLC is  
 
initiated and the recommendation is reinforced when emphasis shifts to  
 
management of the metabolic syndrome . 
 
 The purposes of regular exercise are to promote energy balance to maintain  
 
healthy body weight, to alleviate the metabolic syndrome, and to independently  
 
reduce baseline risk for CHD. 
    
Decision about drug therapy; initiating management of the metabolic 
 
 syndrome: 
 
If the LDL cholesterol goal has not been achieved after 3 months of TLC, a  
 
decision must be made whether to consider adding drug therapy. If drugs are  
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started, TLC should be continued indefinitely in parallel with drug treatment.  
 
Although the apparent ease of drug use is appealing, the additive effect of TLC to  
 
drug therapy in LDL cholesterol lowering is substantial and should not be  
 
overlooked.  
 
 DIABETES MELLITUS: 
 
  Coronary heart disease (macrovascular complications) are the most  
 
important Causes of morbidity and mortality in both type1 and type2 diabetes  
 
mellitus88,89.The results of UKPDS study do not provide clear support that  
 
lowering the Glucose level decreases coronary heart disease risk.90.Treatment of  
 
hyperglycemia is  by both lifestyle modification and pharmacologic treatment. 
 
 Studies on risk Factors for Coronary Heart Disease (CHD)in 
Indians 
 
     A rise in the prevalence of CHD in the early half of twentieth century  and a  
 
 subsequent decline in the latter half have been well  documented  in   the  
 
industrialized countries. However, the scenario is reversed in developing countries  
 
especially India with a steady escalation in prevalence of CHD 4. Earlier studies on 
 
 migrant Indians  in the UK, USA, Canada and Trinidad showed that migrant  
 
Indians had higher rates of CHD compared to the indigenous population. It is  
 
consistently observed that Indians have premature CHD and that their risk for  
 
CHD was two to four times higher than the white European population.91 The   
 
SHARE study showed a CHD prevalence of 10.7% among South Asians  
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compared to 4.6% in Europeans 92 .Within the Indian subcontinent also, there has  
 
been a rapid rise inCHD prevalence. In 1959, Padmavati 93 reported the prevalence  
 
of CHD to be 1.0% and this rose to 4.5% in the year 1975 6 and 7.9% in the year  
 
1996 in subjects aged 20 years and above7. In a  study of subjects aged 40 years 
 
and above by A.Ramachandran et al94, The age-adjusted prevalence of probable  
 
CHD was 3.9% (3.5% in men and 4.5% in women), the prevalence of risk factors  
 
were in the order  of central adiposity >dyslipidemia>hyperinsulinemia (2-h)>  
 
glucose intolerance>obesity > hypertension.  
 
Wo m e n had higher prevalences of increased 2-h insulin (64.2 vs. 49%, p 0.001),  
 
glucose intolerance (43.5 vs. 35.6%, p 0 . 0 0 3 ) ,and obesity  (33.4 vs. 21.4%,  
 
p0 . 0 0 1 ) ,but lower central adiposity (56.6 vs. 64.1%,p 0.001) compared with 
 
 Men 94  
 
The Chennai Urban Population Study (CUPS)9 carried out in 1262  individuals 
 
 > 20 years of age showed the crude prevalence of CHD to be 11% while the age- 
 
adjusted prevalence rate was 9.0%. In CUPS,  LDL cholesterol and age were risk 
 
 factors for CHD but serum triglyceride levels did not come out as an independent  
 
variable.The mean HDL was 40mg./dl which is low in our population 9  
 
Thus the prevalence of CHD appears to be ten times higher in India  
 
compared to that reported 40 years ago and the prevalence of CHD in urban  
 
Indians is fast approaching the figures reported in migrant Indians.9 
 
Data from the Jaipur Heart Watch-2 95, on 1800 subjects based on a stratified  
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sampling technique reported an escalation in the prevalence rates of conventional 
 
coronary heart disease risk factors like obesity, diabetes and dyslipidemia among  
 
North Indians compared to the figures noted in 1990. Hypertension was present in  
 
200 Men (36.4%) and 215 women (37.5%). Diabetes was present in 72 men  
 
(13.1%) and 65 women (11.3%). Truncal obesity was widely prevalent. The most  
 
common dyslipidemia in both men and women was low HDL-cholesterol (men 
 
54.9%, women 54.2%). Prevalence of high total- and LDL-cholesterol and  
 
triglycerides was also seen in significant proportions 95 
 
 Achari and Thakur 96 report on a large retrospective study on 5748 CHD patients  
 
and 8103 healthy normals.Serum cholesterol levels, LDL cholesterol levels and  
 
total cholesterol to HDL ratio were higher among the CHD subjects compared to  
 
normals. The study also makes another interesting observation that there is a lack  
 
of association of serum triglycerides levels with CHD 96 
 
In the case-control study by Burman et al, again LDL cholesterol levels and total  
 
cholesterol/HDL cholesterol ratio and Lp(a) levels were higher in CHD patients  
 
compared to controls but there was no significant difference in serum triglyceride  
 
levels.97 Another large clinic-based study on 17,855 type 2 diabetic subjects  
 
looked at the association of isolated hypercholesterolemia and isolated  
 
hypertriglyceridemia with CHD 98. The prevalence of CHD was significantly  
 
higher among patients with isolated hypercholesterolemia, isolated high LDL and  
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isolated low HDL cholesterol compared with normalipidemic individuals, but not  
 
in those with isolated hypertriglyceridemia.There appears to be differences in lipid  
 
associations with CHD between native and migrant Indians. In migrant  
 
indians, serum triglyceride levels have been consistently found to be associated  
 
with CHD 99   .However in native Indians, LDL cholesterol and total  
 
cholesterol/HDL cholesterol Ratio appears to be more important. One factor which  
 
is common to all Indians is a low HDL cholesterol levels 99 In the face of low  
 
HDL cholesterol levels, even moderate elevation of LDL cholesterol appears to be  
 
sufficient to produce an atherogenic profile. However,  the role of triglycerides  
 
cannot be completely ruled out as the link between hypertriglyceridemia and CHD  
 
has been shown in several studies.  Increased production of small VLDL in  
 
response to hypertriglyceridemia could contribute to atherosclerosis.This is  
 
confirmed by the presence of triglyceride-rich lipoproteins in the human atheroma.  
 
Moreover, increase in triglyceride levels are associated with low HDL cholesterol  
 
and with small dense LDL molecules (Phenotype B)  ‘Atherogenic  
 
dyslipidemia’ is associated with metabolic syndrome and may be responsible for  
 
accelerated atherosclerosis 94 .It is opined that although the total cholesterol levels  
 
in Asian Indians is similar or lower as compared to caucasians 100 atherogenic  
 
dyslipidemia is more common, which may contribute to CHD. Recently an  
 
increased prevalence of small dense LDL in migrant Asian Indians has been  
 
shown in a study conducted in USA 101. 
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Prevalence of elevated LDL cholesterol defined by the NCEP guidelines levels is 
 
only 38.8% among CHD subjects in the study done by Achari 96.This suggests  
 
that either the cut-off used for elevated LDL cholesterol is not appropriate among  
 
Indians or that more than 60% of the CHD is not explained by elevated LDL 
 
cholesterol levels. A similar finding was observed in the clinic study 98 done on  
 
17,855 type 2 diabetic patients that the prevalence of myocardial infarction was  
 
2.9% in subjects with LDL levels below 100 mg/dl compared to 61% in subjects  
 
with LDL above 100 mg/dl. This could mean that in Indians, even those with LDL  
 
below the cut-off of NCEP  have a high risk for CHD suggesting that aggressive 
 
lipid lowering is justified in Indian In this regard the findings of Heart Protection  
 
Study are of great interest. The main message from that study is to “treat high  
 
risk patients with high dose-statin irrespective of their baseline cholesterol  
 
levels”102. This seems to be most applicable to Indians, where the threshold of  
 
LDL cholesterol for CHD appears to be lower than that demonstrated in Western  
 
populations. The main limiting factors of course would be the cost. 
 
Recently, a number of newer coronary heart disease risk factors have been  
 
Identified .These factors are of great interest in native Indians where more than  
 
60% of the CHD remains unexplained by conventional risk factors. Comparative  
 
studies on newer risk factors illustrated that Asian Indians have higher C-reactive  
 
protein,plasminogen activator inhibitor (PAI 1) and homocysteine levels 103 . 
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Lipoprotein (a) levels have been consistently shown to be elevated among Asian 
 
Indians compared to other ethnic groups suggesting a genetic predisposition to  
 
coronary artery disease.104,105.  The study by Burman, et al 97 done on 20 CHD  
 
patients and 20 healthy normals showed that Lp(a) level was associated with  
 
CHD. This confirms several earlier reports from India 106. 
 
Given that India is a large country with tremendous urban-rural differences and  
 
regional variations large, multicentre prospective long-term follow-up studies  
 
addressing non-communicable diseases like diabetes, hypertension and CHD 
 
are the urgent need of the hour.  
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MATERIAL AND METHODS: 
This study was conducted at Govt. Stanley Medical College & Hospital, 
Chennai.  This study was conducted during the period of one year Jan 2005- 
December 2005, 200 asymptomatic subjects attending the MASTER HEALTH 
CHECKUP CLINIC of Govt. Stanley Medical college & hospital were taken up 
for the study 
INCLUSION CRITERIA:                 
Men aged ≥ 45 years and women aged ≥55 years with no previous history 
Of  coronary heart disease, cerebrovascular disease , peripheral vascular                 
disease, Diabetes mellitus, Hypertension were taken up for the study. 
EXCLUSION CRITERIA: 
Subjects with known history Of  coronary heart disease, cerebrovascular     
disease ,peripheral vascular disease, Diabetes mellitus, Hypertension. 
METHODS: 
A total of 200 asymptomatic subjects were taken up for the current study. 
All were  subjected to history taking, thorough clinical examination and 
investigations that included past history of diabetes, dyslipidemia, hypertension, 
coronary heart disease, cerebrovascular disease, peripheral arterial disease and 
renal disorder; family history of hypertension, diabetes, dyslipidemia, premature 
coronary heart disease, cerebrovascular disease and renal disorder; personal 
history of physical activity and smoking  
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The individuals were then subjected  to  thorough physical examination. 
BLOOD PRESSURE: 
Two sets of blood pressure reading were taken 5 minutes apart, with patient 
in sitting position after 5 minutes of rest.The first and the fifth korotkoff’s sounds 
were used to define systolic and diastolic blood pressure respectively.Blood 
pressure was taken in both arms and the higher of them was taken into 
consideration.The average of the two readings were taken for diagnosis.Subjects 
were termed hypertensive when blood pressure reading ≥140/90 according to JNC 
VII criteria 107. 
ANTHROPOMETRIC MEASUREMENTS: 
 
Height 
 
Height was measured by fixing a tape measure to a wall and measuring the height  
 
with a movable headboard, with measures to the nearest centimeter. Subjects were  
 
asked to stand upright without shoes, with their back against the wall,heels  
 
together and eyes directed forward. 
 
Weight 
 
Weight was measured with a traditional spring balance which was kept on a firm  
 
Horizontal surface. The ‘’Zero’’ was checked each day and calibration was done  
 
with reference to an individual of ‘’known’’ weight. The subjects were asked to  
 
wear light clothing and weight was recorded to the nearest 0.5 kg. 
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The body mass index(BMI) was calculated using the formula:   
weight/height2(kg/m2) 
Subjects with BMI 25-29.9 kg/m2 were labelled overweight and BMI≥30 as  
 
Obese108 
 
Waist: 
 
Waist circumference was measured using a non stretchable fibre measure tape.  
 
The subjects were asked to stand erect in a relaxed position with both feet  
 
together. One layer of light clothing was accepted. Waist girth was measured at  
 
the  midpoint between the iliac crest and the lower margin of the ribs. Waist  
 
circumference was measured to the nearest centimeter. Waist circumference  
 
≥90cm in men and ≥80 cm in women was taken as evidence of abdominal  
 
0besity58. 
 
HIP: 
 
Hip girth was recorded at the greatest trochanter (the widest portion of the hip) on  
 
both sides.Measures were made to the nearest centimeter. 
 
  waist-Hip ratio(WHR) calculated as waist circumference in cm divided by 
hip circumference in cm..Truncal obesity was diagnosed if Waist-Hip ratio(WHR) 
>0.9 in men and >0.8 in women109,49. 
Physical inactivity was defined as less than 30 minutes a day of moderate 
physical activity on most days of the week. 
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A thorough physical examination which included peripheral vascular. 
coronary heart disease, respiratory, abdominal, nervous system and fundus 
examination was done. An 8 hour fasting blood sample was taken for biochemical 
investigations. A 2-hour post prandial blood sample was taken after giving 
75g oral glucose for postprandial blood sugar estimation. 
Biochemical  investigations:  
The following biochemical in investigations were done; fasting(FBS) and 
2-hour postprandial blood sugar(PPBS)- Diabetes mellitus was considered if 
FBS≥126mg/dl and/or PPBS≥200,Impaired fasting glucose(IFG) FBS≥100mg/dl 
and.Impaired glucose tolerance(IGT) PPBS≥140 mg/dl 110 were noted. 
Blood urea and serum creatinine was measured. 
Lipid profile was evaluated with Total cholesterol(TC), HDL 
cholesterol(HDL-C) and triglycerides(TGL). LDL cholesterol (LDL-C) was 
estimated  using   Friedwald equation [LDL-C=TC-(HDL+TGL/5)]111 . 
Dyslipidemia   was considered when TC≥200mg/ dl, LDL≥130mg / dl, 
TGL≥150mg / dl, HDL <40mg/dl 49. 
Urine examination was done to assess urine sugar and albumin. 
A 12-lead ECG was taken to assess the presence of coronary heart disease 
.Echocardiography was carried out to assess the presence of regional wall motion 
abnormality. Ultrasonogram was done to assess the renal status. 
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From these data the following risk factors which modify LDL goal were 
categorized 49 
            RISK FACTORS MODIFYING LDL GOALS 
            CIGARETTE SMOKING 
            HYPERTENSION(BP≥140/90mm Hg or on anti-hypertensive medication) 
            LOW HDL CHOLESTEROL(<40mg/dl)* 
            Family H/o Premature CHD(first degree relative men≤55,women≤65) 
            AGE(men≥45,women≥55) 
All the subjects in  our study had minimum one risk factor modifying LDL 
goal which   was age( men≥45,women≥55). 
The subjects were divided into the following risk categories according to 
ATPIII Guidelines49 
   Categories of Risk for Coronary Heart Disease (CHD) Risk Categories 
 
                       Established CHD & CHD risk equivalents 
 
                               Multiple (2+) risk factors 
 
                                     0–1 risk factor 
 
 Established CHD and CHD risk equivalents: 
 
Coronary heart disease:. Persons with CHD are at very high risk for future CHD  
 
events (10-year risk >20 per-cent). Several clinical patterns constitute a diagnosis 
 
 of CHD; these include history of acute myocardial infarction, evidence of silent  
 
myocardial infarction or myocardial ischemia (by ECG), history of unstable  
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angina and stable angina pectoris, and history of coronary procedures (coronary  
 
angioplasty and coronary artery surgery) 
 
Other clinical atherosclerotic diseases: Persons in this subcategory have a CHD  
 
risk equivalent. Included are those with peripheral arterial disease, abdominal  
 
aortic aneurysm, carotid artery disease (symptomatic [e.g., transient ischemic  
 
attack or stroke of carotid origin] or >50 percent stenosis on angiography or  
 
ultrasound), and likely other forms of clinical atherosclerotic disease (e.g., renal  
 
artery disease). 
 
Diabetes mellitus:. ATP III counts diabetes as a CHD risk equivalent.  
 
Framingham risk score: 
The Framingham risk score(FRS) for estimating 10-year CHD risk49 was 
utilised for further risk stratification(Annexure1,2). Risk factors used in 
Framingham scoring include age , total cholesterol, HDL cholesterol, blood 
pressure and cigarette smoking.   
 Framingham scoring divides persons with multiple risk factors into those 
 
 with 10-year risk for CHD of >20%, 10-20%, and <10%. 
          
            Subjects were further categorized as  
 
                  High risk:    CHD* or CHD risk equivalents/10-year risk >20% 
    
                 Moderately high risk: 2 or more risk factors(10-year risk 10% to 20%) 
 
                 Moderate risk: 2 or more risk factors (10-year risk<10%) 
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       Low risk: 0–1 risk factor*(*Most persons with 0-1 risk factor have a       
10-year risk of CHD <10%) 
    ASSESSMENT OF NO. OF RISK FACTORS MODIFYING LDL GOAL 
 
 
 
  
 CHD/CHD Equivalents         Multiple(2+) risk factors          0-1 risk factor* 
             or 
FRS > 20% 10 year CHD                            
 Risk                                                                       FRS                                     
 
                                           <10%     10-20%     >20%                  <10%     
 
  High risk                    Moderate   Moderately  High risk           Low risk 
                                       Risk          High risk  
   
  
  (*Most persons with 0-1 risk factor have a 10-year risk of CHD <10%) 
 
The clinical features of metabolic syndrome were evaluated using 
AHA/NHLBI criteria 58-metabolic syndrome was said to be present if any three of 
the following risk factors were present 
                 Risk factor                                Defining level                                                             
         Abdominal obesity                     Men≥90cm, women≥80cm 
          Elevated triglycerides                    ≥150mg/dl  
Reduced HDL-C                          <40mg/dl men,<50mg/dl women 
Elevated blood pressure                 ≥130/85mmHg 
Elevated fasting glucose              ≥100mg/dl  
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STATISTICAL ANALYSIS: 
Student’s t test was used to analyse quantitative variables and Chi square test for  
 
qualitative variables.A p value of <0.05 was considered as significant. 
 
             
               After evaluation of subjects for coronary heart disease risk factors and  
 
Categorization into appropriate risk categories according to ATP III guidelines,the 
 
individuals were recommended therapeutic life style changes( cessation of  
 
Smoking, increased physical activity, dietary changes), anti-hypertensives for 
 
 control of hypertension, glycemic control by appropriate medications and lipid 
 
lowering therapy to achieve the LDL goal for the respective risk  
 
categories(Table 6)                          
                                                     TABLE 6 
 
                   10 year CHD risk 
 
            LDL cholesterol  goal 
 
                   >20%(High risk) 
 
              <100mg/dl 
  10-20%(2+ risk factors)-moderately       
high risk 
 
              <130mg/dl 
     <10%(2+ risk factors)-moderate risk  
              <130mg/dl 
             <10%(0-1 risk factor)-low risk               <160mg/dl 
 
 
                                                                    
                                             
 47
                                        RESULTS 
200 subjects were taken up for the study out of which 128(64%) were men 
and 72(36%) were women. The mean age was  52.1 in men and 57.9 in women. 
The age structure of subjects in both sexes is shown in Table 7.                                        
 
                                AGE –TABLE 7  
AGE MALE 
(45-78)(n=128) 
FEMALE 
(55-80)(n=72) 
OVERALL 
(n=200) 
45-50 70(54.7)* 0 70(54.7) 
51-55 19(14.8) 26(36.1) 45(22.5) 
56-60 20(15.6) 35(48.6) 55(27.5) 
61-65 11(8.6) 8(11.1) 19(9.5) 
66-70 5(3.9) 0 5(3.9) 
71-75 2(1.6) 2(2.8) 4(2.2) 
76-80 1(0.8) 1(1.4) 2(1) 
MEAN 52.1 57.9  
*Figures in parentheses denote percentages 
 
The mean, range and standard deviation of the various clinical and      
biochemical variables of the subjects is shown in Table 8.  
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                                                Table 8 
VARIABLES MEAN S.D MIN MAX 
M 52.1 7.7 45 78 AGE 
(Yrs) F 57.9 4.5 55 80 
M 133.9 23.4 90 200 Systolic BP 
(mm Hg) 
 
F 143.3 23.5 100 190 
M 84.9 11.1 60 120 Diastolic BP 
(mm Hg) F 87.4 12.2 60 120 
M 23.6 4.3 13.75 34.6 BMI 
F 24.8 4.96 13.3 35.6 
M 0.92 0.07 0.78 1.1 WHR 
 F 0.84 0.06 0.72 1.1 
M 86.4 10.1 58 109.5 Waist 
Circumference 
(cm) F 83.4 10.8 55 108 
M 98.4 31.7 50 250 FBS  
(mg/dl) F 94.8 24.3 60 185 
M 151.6 67.5 72 415 PPBS 
(mg/dl) F 138.6 43.9 84 293 
M 205.5 50.6 94 340 SERUM T.C 
(mg/dl) F 204.3 55.2 115 415 
M 139.6 46.8 55 265 LDL 
(mg/dl) F 139.3 51.7 66 330 
M 142.8 58.4 47 396 TGL 
(mg/dl) F 129.3 37.1 71 279 
M 37.2 5.5 22 50 HDL 
(mg/dl) F 39.1 6.3 21 58 
M 28.5 11.7 9 79 VLDL 
(mg/dl) F 25.8 8 14 56 
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The  coronary heart disease risk factors analysed in the subjects  
  are shown in table 9           TABLE 9 
RISK 
FACTORS 
MEN-N=128(64) WOMEN-N=72(36) TOTAL(N=200) 
smoking 52(40.6)* 0 52(26) 
Physical 
inactivity 123(96.1) 72(100) 195(97.5) 
H/o prem.CHD 5(3.9) 3(4.2) 8(4) 
Overweight 
(BMI25-29.9) 37(28.9) 23(31.9) 60(30) 
Obesity 
(BMI≥30) 12(9.4) 12(16.7) 24(12) 
Truncal obesity 
(WHR>0.9 
men,>0.8 
women) 
64(50) 43(55.1) 107(53.5) 
96(48) Abdominal 
obesity 
(≥90cmmen≥80
cm women)  
50(39.1) 46(63.9) 
p=0.001 
Hypertension(≥
140/90mm Hg) 52(40.6) 38(52.8) 90(45) 
IFG/IGT 43(33.6) 18(25) 61(30.5) 
DIABETES 20(15.6) 11(15.3) 31(15.5) 
High total 
cholesterol 
(≥200mg/dl) 
67(52.3) 35(48.6) 102(51) 
LDL≥130mg/dl 70(54.7) 39(54.2) 109(54.5) 
65(32.5) TGL≥150mg/dl 48(37.5) 17(23.6) p=0.04 
114(57) Low 
HDL<40mg/dl 81(63.3) 33(45.8) p=0.01 
78(39) Metabolic 
syndrome 42(32.8) 36(50) p=0.01 
       * Figures in parentheses denote percentages 
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    The most common overall major coronary heart disease risk factor was physical   
inactivity present in 97.5% of subjects. Next common risk factor was low HDL 
Cholesterol, present in 57% of subjects. LDL Cholesterol ≥130mg/dl(54.5%),Total 
cholesterol≥200mg/dl(51%),TGL≥150mg/dl(32.5%) were the dyslipidemias  
noted. Hypertension was noted in 45% of subjects. 
Dysglycemia(IFG/IGT) was seen in 30.5% of subjects. Newly diagnosed Diabetes 
mellitus was noted in 15.5% of subjects.30% of subjects were overweight(BMI 
25-29.9)and 12%obese(BMI>30).Truncal obesity(53.5%) and abdominal 
obesity(48%) were noted.Metabolic syndrome was present in 39% of 
subjects.Family history of premature CHD(4%) was rare.Abdominal obesity and 
metabolic syndrome were significantly higher in women. 
Hypertriglyceridemia(TGL≥150mg/dl) and Low HDL<40mg/dl were significantly 
higher in men.(Table 9) 
 
Age wise prevalence of risk factors in men are shown in Table 10 
 
Smoking was common in 61-65 age group(72.7%) and 45-50 age group(42.8%) 
 
 
The prevalence of Hypertension increased after the age of 50 years in men. 
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                       Age wise prevalence of risk factors in men 
 
            
                                              TABLE 10 
RISK FACTOR 45-50 
n=70 
51-55 
n=19 
56-60 
n=20 
61-65 
n=11 
>65 
n=8 
SMOKING 30(42.8)* 6(31.6) 5(25) 8(72.7) 3(37.5) 
Physical inactivity  68(97.1) 19(100) 17(85) 11(100) 8(100) 
Family H/O Prem 
CHD 
2(2.8) 1(5.3) 1(5) 0 1(12.5) 
Overweight 
(BMI 25-29.9) 
24(34.3) 8(42.1) 4(20) 1(9.1) 0 
OBESE 
(BMI≥30) 
6(8.6) 0 3(15) 2(18.2) 1(12.5) 
TRUNCAL  
OBESITY 
39(55.7) 9(47.4) 10(50) 5(45.4) 1(12.5) 
ABDOMINAL 
OBESITY 
29(41.4) 7(36.8) 9(45) 2(18.2) 3(37.5) 
 Hypertension 23(32.8) 10(52.6) 10(50) 5(45.4) 4(50) 
IFG/IGT 19(27.1) 8(42.1) 8(40) 3(27.3) 5(62.5) 
DM 13(18.6) 2(10.5) 1(5) 4(36.4) 0 
TC≥200 mg/dl 41(58.6) 9(47.4) 10(50) 6(54.5) 1(12.5) 
LDL≥130 mg/dl 39(55.7) 10(52.6) 11(55) 8(72.7) 2(25) 
TGL≥150 mg/dl 31(44.3) 7(36.8) 6(30) 3(27.3) 1(12.5) 
HDL<40 mg/dl 44(62.8) 13(68.4) 13(65) 7(63.6) 4(50) 
METABOLIC 
SYNDROME 
22(31.4) 7(36.8) 8(40) 3(27.3) 2(25) 
*Figures in parentheses denote percentages 
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Age wise prevalence of risk factors in female are shown in Table 11 
 
                                           Table 11 
RISK FACTOR 51-55 
n=26 
56-60 
n=35 
61-65 
n=8 
>65 
n=3 
SMOKING 0 0 0 0 
Physical inactivity  26(100)* 35(100) 8(100) 3(100) 
Family H/O Prem 
CHD 
1(3.8) 2(5.7) 0 0 
Overweight 
(BMI25-29.9) 
8(30.8) 12(34.3) 2(25) 1(33.3) 
OBESE(BMI≥30) 5(19.2) 5(14.3) 2(25) 0 
TRUNCAL  
OBESITY 
12(46.1) 25(71.4) 5(62.5) 1(33.3) 
ABDOMINAL 
OBESITY 
16(61.5) 21(60) 7(87.5) 2(66.7) 
  HTN 11(42.3) 17(48.6) 7(87.5) 3(100) 
IFG/IGT 9(34.6) 6(17.1) 2(25) 1(33.3) 
DM 4(15.4) 5(14.3) 2(25) 0 
TC≥200 mg/dl 15(57.7) 15(42.8) 3(37.5) 2(66.7) 
LDL≥130mg/dl 16(61.5) 16(45.7) 5(62.5) 2(66.7) 
TGL≥150mg/dl 7(26.9) 9(25.7) 1(12.50 0 
HDL<40mg/dl 12(46.1) 14(40) 5(62.5) 2(66.7) 
METABOLIC 
SYNDROME 
14(53.8) 14(40) 7(87.5) 1(33.3) 
*Figures in parentheses denote percentages 
 
 
The prevalence of Hypertension increased after the age of 55 years in           
women. 
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The Framingham risk score of the subjects are shown in Table 12 
                                          TABLE 12 
FRAMINGHAM  
RISK SCORE 
MALE 
n=128 
FEMALE
n=72 
OVERALL 
n=200 
<10% 10-yr CHD risk 42(32.8)* 64(88.9) 106(53) 
10-20% 10-yr CHD risk 60(46.9) 8(11.1) 68(34) 
>20% 10-yr CHD risk 26(20.3) 0 26(13) 
*Figures in parentheses denote percentages 
The Risk categories of the subjects are shown in table 13 
                                           TABLE 13 
RISK 
CATEGORY 
MALE 
n=128 
FEMALE 
 n=72 
OVERALL 
  n=200 
LOW 14(10.9)* 14(19.4) 28(14) 
MODERATE 26(10.7) 36(50) 62(31) 
MODERATELY 
HIGH 
46(35.9) 8(11.1) 54(27) 
HIGH(CHD 
EQUIVALENT) 
42(32.8) 14(19.5) 56(28) 
   *Figures in parentheses denote percentages 
 
                  High risk:    CHD or CHD risk equivalents/10-year risk >20% 
    
                  Moderately high risk: 2 or more risk factors(10-year risk 10% to 20%) 
 
                  Moderate risk: 2 or more risk factors (10-year risk<10%) 
 
       Low risk: 0–1 risk factor 
Overall 28% of individuals were in high risk (CHD equivalent) group(men-
32.8%,women19.5%).In men 35.9% were in moderately high risk compared to 
11.1% in women.50% of women were in moderate risk group compared to 10.7% 
in men 
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The multiple risk factor profile modifying LDL goal are shown in Table 14 
                                         TABLE 14 
RISK FACTORS 
MODIFYING LDL 
 GOAL 
MALE 
 n=128 
FEMALE 
  n=72 
OVERALL 
   n=200 
AGE 20(15.6)* 19(26.4) 39(19.5) 
AGE+SMOKING 6(4.7) 0 6(4.7) 
AGE+Hypertension(HTN) 7(5.5) 15(20.8) 22(11) 
AGE+LOW HDL 28(21.9) 15(20.8) 43(21.5) 
AGE+SMOKING+LOW 
HDL 
17(13.3) 
 
0 17(13.3) 
AGE+HTN +LOW HDL 24(18.7) 21(29.2) 45(22.5) 
AGE+SMOKING+HTN 10(7.8) 
 
0 10(7.8) 
AGE+SMOKING+HTN+ 
LOW HDL 
14(10.9) 0 14(10.9) 
AGE+SMOKING+LOW 
HDL+Family H/o prem CHD 
1(0.8) 0 1(0.8) 
AGE+HTN+HDL+ 
Family H/o premCHD 
 
1(0.8) 2(2.8) 3(1.5) 
*Figures in parentheses denote percentages 
 
 Multiple(2+) risk factors that modify LDL goal were present in 84.4% of men and 
 
73.6% of women.Overall the combination of AGE+HYPERTENSION+LOW  
 
HDL(22.5%) and AGE+LOW HDL(21.5%) were common. 
 
The risk factor profile comparision between hypertensive and normotensive  
 
Individuals is shown in table 15 
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                                            Table 15 
RISK FACTORS        HTN 
    MEN=52          
WOMEN=37        
 NON-HTN 
  MEN=76 
  WOMEN=35    
M 24(46.1)* 28(36.8) Smoking 
F 0 0 
M 49(94.2) 74(97.4) Physical inactivity 
F 37(100) 35(100) 
M 2(3.8) 3(3.9) Family H/o premature 
  CHD F 2(5.4) 2(5.7) 
M 19(36.5) 17(22.4) Overweight(BMI25-29.9) 
F 13(35.1) 10(28.6) 
M 8(15.4) 4(5.3) Obesity 
(BMI≥30) F 10(27) 2(5.7) p=0.02 
M 25(48.1) 39(51.3) Truncal 
Obesity 
 
F 25(67.6) 17(48.6) 
M 25(48.1) 25(32.9) p=0.03 Abdominal obesity 
  F 31(83.8) 14(40) p=0.01 
M 16(30.8) 27(35.5) IFG/IGT 
F 9(24.3) 9(25.7) 
M 9(17.3) 11(14.5) DIABETES 
F 6(16.2) 5(14.3) 
M 30(57.7) 37(48.9) High total cholesterol 
(≥200mg/dl) F 21(56.7) 13(37.1) 
M 45(86.5) 25(32.9) p=0.01 LDL≥130 mg/dl 
F 24(64.9) 14(40) 
M 22(42.3) 26(34.2) TGL≥150 mg/dl 
F 8(21.6) 9(25.7) 
M 34(65.4) 47(61.8) Low HDL<40 mg/dl 
F 20(54) 14(40) 
M 27(51.9) 15(19.7) p=0.01 Metabolic syndrome 
F 25(67.6) 11(31.4)  
    *Figures in parentheses denote percentages 
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The risk factor profile comparision between Normal Glucose Tolerance(NGT) and  
 
IFG/IGT/DM subjects is Shown in table 16                                               
                                                     
                                                       TABLE 16 
RISK 
FACTO
RS 
            NGT              IFG/IGT              DM 
 M 
n=65 
F 
n=43 
T 
n=108 
M 
n=43 
F 
n=18 
T 
n=61 
M 
n=20 
F 
n=11 
T 
n=31 
SMOKI
NG 
25 
(38.5)* 
0 25(23.1) 16(37.2) 0 16 
(26.2) 
11 
(55) 
0 11 
(35.5) 
PHYSIC
AL 
INACTI
VITY 
61(93.8) 43(100) 107(99.1) 42(97.7) 18(100) 60 
(98.4) 
20 
(100) 
11 
(100) 
31(100) 
H/oPRE.
CHD 
2(3.1) 1(2.3) 3(2.8) 3(7) 1(5.5) 4(6.5) 0 1(9.1) 1(3.2) 
OVERW
T 
19(29.2) 11(25.6) 30(27.8) 12(27.9) 9(50) 21 
(34.4) 
6(30) 3 
(27.3) 
9(29) 
obesity 6(9.2) 5(11.6) 11(10.2) 4(9.3) 5(27.8) 9(14.7) 2(10) 2 
(18.2) 
4(12.9) 
23 
(74.2) 
 
Truncal 
obesity 
25(38.5) 24(55.8) 49(45.4) 22(51.2) 11(61.1 33 
(54.1) 
16 
(80) 
7 
(63.6) 
p=0.02 
18 
(58.1) 
Abdomin
al 
obesity 
19(29.2) 22(51.2) 41(38) 18(41.9) 16(88.9) 34 
(55.7) 
10 
(50) 
8 
(72.7) 
p=0.03 
HTN 27(41.5) 23(53.5) 50(46.3) 16(37.2) 9(50) 25 
(41) 
9(45) 6 
(54.5) 
15 
(48.4) 
TC 
≥200 
mg/dl 
34(52.3) 21(48.8) 55(50.9) 19(44.2) 8(44.4) 27 
(44.3) 
15 
(75) 
6 
(54.5) 
21 
(67.7) 
23 
(74.2) 
LDL 
≥130 
mg/dl 
35(50.8) 23(53.5) 58(53.7) 20(46.5) 8(44.4) 28 
(45.9) 
15 
(75) 
8 
(72.7) 
p=0.04 
15 
(48.4) 
TGL 
≥150 
mg/dl 
17(26.2) 8(18.6) 25(23.1) 19(44.2) 5(27.8) 24 
(39.3) 
11 
(55) 
4 
(36.4) 
p=0.01 
HDL 
<40 
mg/dl 
37(56.9) 23(53.5) 60(55.5) 31(72.1) 9(50) 40 
(65.6) 
13 
(65) 2 
(18.2) 
15 
(48.4) 
20 
(64.5) 
META
BOLIC 
SYND
ROME 
12(18.5) 14(32.5) 26(24.1) 19(44.2) 13(72.2) 32 
(52.4) 
11 
(55) 
9 
(81.8) 
p=0.01 
*Figures in parentheses denote percentages 
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The individual components of metabolic syndrome in NGT,IFG/IGT/DM  
are shown in table 17                                            
                                      TABLE 17 
             NGT               IFG/IGT                 DM METABOLIC 
SYNDROME 
COMPONENTS 
 
 
     MEN 
     n=12 
 
WOMEN         
n=14 
 
MEN 
    n=19 
 
 WOMEN    
    n=13 
 
 MEN                  
n=11 
 
 WOMEN 
    n=9 
DYSLIPIDEMIA 
(TGL≥150mg/dl 
& or 
HDL<40mg/dl) 
0 0 0 0 1(9.1) 2(22.3) 
ABD.OBESITY+ 
 DYSLIPIDEMIA 
3(25)* 1(7.1) 7(36.8) 4(30.8) 4(36.4) 3(33.3) 
ABD.OBESITY 
        + 
     HTN 
 
0 
 
0 
 
0 
 
0 
 
0 
 
 
0 
 
     HTN 
        + 
 DYSLIPIDEMIA 
 
   
 
 
2(16.7) 
 
 
0 
 
 
3(15.8) 
 
 
1(7.7) 
 
 
2(18.2) 
 
 
1(11.1) 
ABD.OBESITY 
        + 
     HTN 
        + 
DYSLIPIDEMIA 
 
 
7(58.3) 
 
 
13(92.8) 
 
 
9(47.4) 
 
 
8(61.5) 
 
 
4(36.3) 
 
 
3(33.3) 
*Figures in parentheses denote percentages 
The risk categorization in individuals with metabolic syndrome    
                                      TABLE 18               
                                            METABOLIC  SYNDROME 
RISK CATEGORY MALE 
 n=42 
WOMEN 
  n=36 
OVERALL 
    n=78 
LOW 1(2.4)* 3(8.3) 4(5.1) 
MODERATE 3(7.1) 18(50) 21(26.9) 
MODERATELY 
HIGH 
17 (40.5) 5(13.9) 22(28.2) 
HIGH(CHD 
EQUIVALENT) 
21(50) 10(27.8) 31(39.7) 
*Figures in parentheses denote percentages 
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              Risk factors and Risk categorization shown in Table 19                                              
                                                TABLE 19 
 LOW RISK MODERATE 
     RISK 
MODERATELY 
HIGH RISK 
HIGH RISK/ 
CHD EQUIVALENT 
 
RISK FACTOR 
 
 
M 
 
 
N=14 
 
F 
 
 
N=14 
 
 
 
 
M 
 
 
N=26 
 
F 
 
 
N=36 
 
M 
 
 
N=46 
 
F 
 
 
N=8 
 
M 
 
 
N=42 
 
F 
 
 
N=14 
SMOKING 0 
 
0 5 
(19.2) 
0 21(45.6) 0 26(61.9) 0 
Physical 
inactivity  
13(92.8) 14 25 
(96.1) 
36(100) 44(95.6) 8(100) 41(97.6) 14(100) 
Family H/O Prem 
CHD 
0 0 1 
(3.8) 
 
1(2.8) 
3(6.5) 0 1(2.4) 2(14.3) 
Overweight(BMI
25-29.9) 
4(28.6) 5 
(35.7) 
7 
(26.9) 
11 
(30.5) 
14(30.4) 3(37.5) 12(28.6) 4(28.6) 
OBESE 0 1 
(7.1) 
1 
(3.8) 
8 
(22.2) 
5(10.9) 1(12.5) 6(14.3) 2(14.3) 
TRUNCAL  
OBESITY 
6(42.8) 7(50) 
 
12 
(46.1) 
25 
(69.4) 
21(45.6) 4(50) 25(59.5) 10(71.4) 
ABDOMINAL 
OBESITY 
4(28.6) 8 
(57.1) 
9 
(34.6) 
22 
(61.1) 
18(39.1) 7(87.5) 19(45.2) 9(64.3) 
  HTN 0 0 7 
(26.9) 
23 
(63.9) 
23(50) 7(87.5) 22(52.4) 8(57.1) 
IFG/IGT 6(42.8) 7 
(50) 
9 
(34.6) 
8 
(22.2) 
16(34.8) 2(25) 12(28.6) 1(7.1) 
DM 0 0 0 0 0 0 20(47.6) 11(78.6) 
TC≥200 mg/dl 4(28.6) 6 
(42.8) 
 
 
8 
(30.8) 
14 
(38.9) 
24(52.2) 6(75) 31(73.8) 9(64.3) 
LDL≥130 mg/dl 5(35.7) 6 
(42.8) 
9 
(34.6) 
16 
(44.4) 
26(56.5) 6(75) 30(71.4) 11(78.6) 
TGL≥150 mg/dl 1(7.1) 4 
(28.6) 
5 
(19.2) 
8 
(22.2) 
19(41.3) 1(12.5) 23(54.8) 4(28.6) 
HDL<40 mg/dl 0 0 21 
(80.8) 
23 
(63.9) 
 
31(67.4) 6(75) 29(69) 5(35.7) 
METABOLIC 
SYNDROME 
1(7.1) 3 
(21.4) 
3 
(11.5) 
18(50) 17(36.9) 5(62.5) 21(50) 10(71.4) 
figures in parentheses indicate percentages 
 
Newly diagnosed Diabetes mellitus, dyslipidemia, hypertension and smoking were  
 
the important risk factors contributing to high risk categorization in men.                                               
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                                             DISCUSSION 
     The epidemic of coronary heart disease has taken deep roots in  india and many 
other developing countries4.The burden of death and disability due to coronary 
heart disease(CHD) continues to increase2  and in  the absence of  suitable 
preventive efforts is not being controlled112. A  large number of  studies have 
highlighted that the primordial prevention strategy of CHD  involving control of 
three lifestyle-related risk factors- smoking, physical inactivity and aberrant diet-is 
the most cost-effective method112. 
  Major coronary risk factors: smoking , hypertension , high low density 
lipoprotein (LDL) Cholesterol , diabetes , obesity , truncal  obesity , insulin  
resistance , low high-density lipoprotein(HDL)-cholesterol are secondary 
manifestations of these deviant lifestyles and explain more than 90% of the 
incidence of CHD worldwide113   Retrospective analysis of previous Indian CHD 
and risk factor epidemiological studies have reported increasing prevalence of the 
major coronary risk factors such as smoking , hypertension , diabetes , 
hypercholesterolemia ,obesity  and  truncal obesity4,7,112.The increase in these risk 
factors correlates positively with the increasing CHD in india 8 
  Evaluation of coronary heart disease risk factors can be done by many 
methods.In this study ATPIII 49 guidelines was used to evaluate the coronary heart 
disease risk factors and for risk stratification.ATP III identifies three categories of 
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risk for CHD that modify goals and  modalities of LDL-lowering therapy: 
established CHD and CHD risk equivalents, multiple (2+) risk factors, and 0–1 
risk factor. Risk assessment for determining the 10-year risk for developing 
coronary heart disease may be carried out using Framingham risk 
scoring(Annexure 1,2). The risk status in persons without clinically manifest 
coronary heart disease(CHD) or other clinical forms of atherosclerotic disease is 
determined by a two step procedure.First, the number of risk factors modifying 
LDL goal is counted 49                          
                      RISK FACTORS MODIFYING LDL GOALS 
   CIGARETTE SMOKING 
   HYPERTENSION(BP≥140/90mm Hg or on anti-hypertensive medication) 
    LOW HDL CHOLESTEROL(<40mg/dl)* 
    Family H/o Premature CHD(first degree relative men≤55,women≤65) 
     AGE(men≥45,women≥55) 
*HDL>60mg/dl counts as a ‘negative’ risk factor;its presence removes 1 
risk factor from the total count.    
Second, for persons with multiple(2+) risk factors,10 year risk assessment 
is carried out with Framingham scoring as shown in Annexure 1,2. 
Risk factors used in Framingham scoring include age ,total cholesterol,HDL  
 
cholesterol,blood pressure and cigarette smoking. 
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         ASSESSMENT OF NO. OF RISK FACTORS MODIFYING LDL GOAL 
 
 
 
  
 CHD/CHD Equivalents         Multiple(2+) risk factors          0-1 risk factor* 
             or 
FRS > 20% 10 year CHD                            
 Risk                                                                       FRS                                     
 
                                           <10%     10-20%     >20%                  <10%     
 
  High risk                    Moderate   Moderately  High risk           Low risk 
                                       Risk          High risk  
   
  
  (*Most persons with 0-1 risk factor have a 10-year risk of CHD <10%) 
  
a. Identification of persons with CHD and CHD risk equivalents: 
 
Coronary heart disease:. Persons with CHD are at very high risk for future CHD  
 
events (10-year risk >20 per-cent). Several clinical patterns constitute a diagnosis 
 
 of CHD; these include history of acute myocardial infarction, evidence of silent  
 
myocardial infarction or myocardial ischemia(by ECG), history of unstable angina  
 
and stable angina pectoris, and history of coronary procedures (coronary  
 
angioplasty and coronary artery surgery) 
 
Other clinical atherosclerotic diseases: Persons in this subcategory have a CHD  
 
risk equivalent. Included are those with peripheral arterial disease, abdominal  
 
aortic aneurysm, carotid artery disease symptomatic(e.g., transient ischemic  
 
attack or stroke of carotid origin ) 
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Diabetes mellitus:. ATP III counts diabetes as a CHD risk equivalent.  
 
Multiple risk factors and 10-year risk for CHD >20 percent: 
 
Based on 10-year risk assessment using Framingham scoring, a person 
 
 in this category can be said to have a CHD risk equivalent. 
 
(b) MULTIPLE(2+) RISK FACTORS:  
 
Individuals who fall into the multiple (2or more)risk factor category may be  
 
further subclassified according to their 10-year CHD risk using the Framingham  
 
scoring system  into those with 10-year CHD risk of more than 20 percent,10 to 20  
 
percent.and less than 10 percent.This further identifies individuals whose 10-year  
 
risk may warrant intensive management despite having a milder risk factor profile 
 
 and allows better  targeting of treatments to those who will benefit most.  
 
   
Further risk stratification of individuals is done by ATPIII guidelines as 
 
                    
                  High risk:    CHD* or CHD risk equivalents/10-year risk >20% 
    
                 Moderately high risk: 2 or more risk factors(10-year risk 10% to 20%) 
 
                 Moderate risk: 2 or more risk factors (10-year risk<10%) 
 
       Low risk: 0–1 risk factor* 
(*Most persons with 0-1 risk factor have a 10-year risk of CHD <10%) 
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In our study 200 asymptomatic subjects(men≥45,women≥55) attending 
master health checkup were analysed for major coronary heart disease risk factors. 
Emerging lipid risk factors;Lipoprotein remnants,Lipoprotein(a), SmalldenseLDL, 
.Apolipoproteins: ApoB,  ApoA1 and non-lipid risk factors;.Homocysteine,                        
fibrinogen,activated factor VII,Plasminogen activator inhibitor(PAI),were not 
evaluated. 
     There were 128-male,72-female subjects.Mean age in men was 52.1,women 
57.9. The most common overall major coronary heart disease risk factor was 
physical   inactivity present in 97.5% of subjects. Next common risk factor was 
low HDL Cholesterol present in 57% of subjects. LDL Cholesterol 
≥130mg/dl(54.5%),Totalcholesterol≥200mg/dl(51%),TGL≥150mg/dl(32.5%) 
were the dyslipidemias noted.Hypertension was noted in 45% of subjects. 
Dysglycemia (IFG/IGT)110 was seen in 30.5% of subjects. Newly diagnosed 
Diabetes mellitus was noted in 15.5% of subjects.30% of subjects were 
overweight(BMI 25-29.9)and 12%obese(BMI≥30).Truncal obesity(53.5%) and 
abdominal obesity(48%) were noted.Metabolic syndrome was present in 39% of 
subjects.Family history of premature CHD(4%) was rare. (Table 9).  
Men: 
Physicalinactivity(96.1%),Smoking(40.6%)hypertension(40.6%),dysglycemia(IFG
/IGT) –43%,dyslipidemia were the important coronary heart disease risk factors in 
men. Low HDL<40(63.3%) and High LDL≥130(54.7%) were the important 
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dyslipidemias.Newly diagnosed Diabetes mellitus (CHD equivalent) seen in15.6% 
Obesity(9.4%) and family h/o premature CHD(3.1%) were low.32.8% had the 
metabolic syndrome as diagnosed by AHA/NHLBI criteria.Hypertriglyceridemia 
and low HDL were significantly more in men. (Table 9). ECG evidence of 
Coronary Heart disease seen in 5.5% 
Women: 
Physical inactivity(100%),truncal obesity(55.1%) and abdominal obesity 
(63.9%),hypertension(52.8%) and dyslipidemia were the important coronary heart 
disease risk factors. In women high LDL(54.2%) was the most common 
dyslipidemia. Newly diagnosed Diabetes mellitus (CHD equivalent) seen in15.3%. 
50% had the metabolic syndrome as diagnosed by AHA/NHLBI criteria.Smoking 
was not present in women. Abdominal obesity and metabolic syndrome was 
significantly more in women(Table 9). ECG evidence of Coronary Heart disease 
seen in 4.2%.  
Prevalences of risk factors: 
The overall  prevalences  of risk factors in our study in descending order of  
 
frequency were physical inactivity> dyslipidemia  >  truncal obesity  
 
(WHR > 0.9Men , > 0.8  men )  > Glucose  intolerance (IFG / IGT / DM ) > 
Hypertension > obesity  (BMI≥30).   This is in contrast to the  Study done by 
A.Ramachandran et al94 who in a population>40 years reported the  
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prevalence of risk factors were in the descending order of frequency 
 
truncal obesity >dyslipidemia> glucose intolerance(IFG/IGT/DM)>obesity >  
 
hypertension.  
    
The overall prevalence of hypertension in our study was 45%.Prevalence of 
hypertension is higher among women(52.8%) than men(40.6%)(Table 8).This is in 
contrast to Chennai urban population study( CUPS)114 where overall prevalence 
was 21% and a higher prevalence among men(22.8%) than women(19.7%).This 
difference may be because of an older age group in our study . 
Abdominal obesity was significantly higher in hypertensive subjects of 
both sexes than non-hypertensives(Table 15).This is similar to the CUPS114.There 
was no significant difference in smoking rates between hypertensive and non-
hypertensive men which is similar to CUPS114 .LDL cholesterol was significantly 
higher in hypertensive men similar to CUPS114.Metabolic syndrome was 
significantly higher in hypertensive groups of both sexes(Table 15) 
Table 10 and Table 11 show the age wise distribution of hypertension.The 
prevalence of hypertension is increasing after the age of 50 years in both 
sexes.Virtually all studies have shown a rise in blood pressure with age,which was 
also observed in our study 
The most common dyslipidemia in men was low HDL(63.3%) which is 
similar to Jaipur heart watch 2 study 95. In women high LDL was the most 
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common dyslipidemia.The mean HDL(37.9) was low in our study group which is 
similar to CUPS114 where the mean HDL was 40. 
METABOLIC SYNDROME: 
Individuals with IFG/IGT/DM had a clustering of coronary heart disease 
risk factors and the prevalence of metabolic syndrome as diagnosed by 
AHA/NHLBI criteria was 56.5% compared to 24.1% in normal glucose tolerance 
(NGT) individuals which was statistically significant(Table 16).Similar reports 
have been published in north india which showed a prevalence of metabolic 
syndrome was 61% in IFG compared to 16.1% in NGT115. 
Truncal obesity and abdominal obesity was significantly more in 
IFG/IGT/DM than NGT individuals in both sexes. Dyslipidemia 
(LDL≥130mg/dl,TGL≥150mg/dl) was significantly more in persons with 
IFG/IGT/DM than NGT individuals. (Table 16). 
Among individuals with metabolic syndrome the combination of abdominal 
obesity+Hypertension+Dyslipidemia was the commonest in both NGT and 
IFG/IGT/DM Individuals.(Table 17) 
RISK STRATIFICATION: 
 Framingham risk score >20% 10 yr CHD risk was 20.3% in men while 
46.9% were in the 10-20% 10 yr  CHD risk score range.In women 88.9% 
individuals were in <10% 10 yr CHD risk score range,>20% 10 yr CHD risk –nil 
.(Table 12) 
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Overall 28% of individuals were in high risk (CHD equivalent) group(men-
32.8%,women19.5%).In men 35.9% were in moderately high risk compared to 
11.1% in women.50% of women were in moderate risk group compared to 10.7% 
in men .(Table 13) 
Multiple(2+) risk factors were present in 84.4% men and 73.6% 
women(Table14).Inspite of only a small difference between the presence of 
multiple(2+) risk factors in both sexes, moderate risk group(50%) was the 
commonest risk group in women compared to high risk (32.8%)and moderately 
high risk(35.9%) being commoner in men.(Table 13) 
This can be attributed to the fact that hypertriglyceridemia and low HDL 
cholesterol which are  part of atherogenic dyslipidemia was significantly more in 
men and smoking was an additional risk factor present only in men(Table9,19) 
Diabetes mellitus was the important risk factor contributing to high 
risk(CHD equivalent) in women since ATPIII considers Diabetes as CHD 
equivalent. 
There was a statistically significant difference in 10 yr CHD risk scores and 
risk categorization between men and women.Men being more prone for higher 10 
yr CHD risk scores and risk categorization.   
This study has highlighted the fact that asymptomatic subjects attending our 
MASTER HEALTH CHECKUP CLINIC had various grades of risk factors 
 necessitating intensive intervention. 
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It is recommended that evaluation of coronary heart disease risk factors 
utilizing (a)Multiple risk factor analysis (b) Framingham 10 year CHD risk score 
and(c)Risk categorization according to ATP III guidelines be done in individuals 
for primary prevention of coronary heart disease. 
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SUMMARY 
1.Total no of subjects-200. Men-128(64%),women-72(36%)      
2.The overall major risk factors  were  
    (a)  physical inactivity(97.5%),(men-96.1%,women-100%) 
     (b)Dyslipidemia 
                        HDL-C<40mg/dl-57%, (men-63.3%,women-45.8%) 
                        LDL-C≥130mg/dl-54.5%(men-54.7%,women-54.2%) 
                      Total cholesterol≥200mg/dl-51%(men-52.3%,women-48.6%) 
                       TGL≥150 mg/dl-32.5%(men-37.5%,women-23.6%) 
    (c)Truncal obesity-53.5%(men-50%,women-55.1%) 
   (d) Dysglycemia(IFG/IGT)-30.5%(men-33.6%,women-25%) 
  (e) Diabetes mellitus-15.5%  (men-15.6%,women-15.3%) 
  (f) Abdominal obesity- 48%(men-39.1%,women-63.9%) 
  (g)Overweight-30%(men-28.9%,women-31.9%) 
  (h) obesity-12%(men-9.4%,women-16.7%) 
   (h)Smoking-26% (only in men)  
   (i)Family H/o premature CHD was rare-4%(men-3.9%,women-4.2%) 
3.Metabolic syndrome-39%(men-32.8%,women-50%) and abdominal                  
 obesity  significantly more in women . 
4.Hypertriglyceridemia and low HDL significantly more in men 
5.Multiple risk factors modifying LDL goal (2+ risk factors) present in 
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   84.4% men, 73.6%  women. Two  risk factors(32.1% men,41.6% women) 
three risk factors (39.8% men , 29.2% women) , four risk factor                        
combination (12.5%  men , 2.8% women) 
6.Framingham 10 year CHD risk score 
            <10% 10 yr CHD risk-men 32.8%,women 88.9% 
             10-20% 10 yr CHD risk-men 46.9%,women 11.1% 
            >20% 10 yr CHD risk-men 20.3%,women 0% 
7.Risk categorization 
 Low risk(0-1 risk factor)-men 10.9%,women 19.4% 
 Moderate risk(2 or more risk factors+ 10 yr  risk<10%)-men 10.7%, 
                                                                                          Women 50% 
Moderately High risk(2 or more risk factors+10 yr risk 10-20%) 
                                                                            Men-35.9% 
                                                                           Women-11.1% 
High risk(CHD or CHD risk equivalents/10 year risk>20%) 
                                                                        Men-32.8% 
                                                                    Women-19.5%   
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CONCLUSION 
I. Evaluation of coronary heart disease risk factors utilizing(a)Multiple risk 
factor analysis(b)Framingham 10 year CHD risk score(c)Risk 
categorization according to NCEP-ATP III guidelines was valuable.    
It is essential to utilize all these parameters to evaluate coronary heart 
disease risk factors.       
 
II. This study has highlighted that asymptomatic subjects attending              
MASTER HEALTH CHECKUP CLINIC had various grades of risk                  
Factors which required intensive intervention for risk modification             
utilizing   NCEP-ATPIII guidelines. This would be very valuable to select            
asymptomatic high risk individuals for intensive management. It is also            
essential that moderate and moderately high risk groups be also targeted for            
risk management.      
 
III. Metabolic syndrome was present in a significant number of subjects.                
Evaluation for metabolic syndrome targets a set of multiple risk factor            
Groups who might have high or moderate to moderately high risk for CHD           
which   needs intensive management for risk modification.  
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                                           PROFORMA 
NAME:                                                                IP NO: 
AGE:                                                                    ADDRESS: 
SEX:  
OCCUPATION 
EDUCATION:                                                         EARNING:                                                                   
PAST HISTORY 
1. Hypertension 
2. Diabetes mellitus 
3. coronary heart disease 
4. other illness  
PERSONAL HISTORY: 
1. Smoking                 No of cigarettes /day:        Duration in years: 
2. Alcohol 
3. Physical Activity 
 
FAMILY HISTORY OF PREMATURE CHD : 
ANTHROPOMETRIC MEASUREMENTS: 
          1.WEIGHT(in Kg) : 
          2.HEIGHT(in cm) : 
          3.BMI(Wt/Ht2 ) : 
          4.WAIST CIRCUMFERENCE( in cm) : 
            5.HIP CIRCUMFERENCE( in cm) : 
            6.WAIST/HIP RATIO : 
 
 CLINICAL EXAMINATION: 
          Pulse rate   :                        Blood pressure :                      JVP: 
CVS: 
RS: 
ABDOMEN: 
CNS: 
INVESTIGATION: 
 1.URINALYSIS: 
      a.Albumin: 
      b.Sugar  : 
 2.BLOOD CHEMISTRY: 
    a.Glucose(mg/dl):  FBS                          PPBS 
    b.Urea (  mg/dl) : 
    c. Creatinine(mg/dl) : 
    d.Lipid Profile : 
             Total Cholesterol 
             HDL-C 
             TGL 
             VLDL-C 
              LDL-C 
 3. 12 LEAD ECG: 
 4. ECHOCARDIOGRAPHY: 
 5. ULTRASONOGRAM ABDOMEN: 
 6.FRAMINGHAM RISK SCORE(10 Yr CHD RISK) : 
 
              
    
ANNEXURE-1 
       
Estimate of 10-Year CHD Risk for Men (Framingham Point Scores) 
 
                                         AGE,Yr                    POINTS 
                                             20-34                          -9 
                                             35-39                          -4         
                                             40-44                           0                 
                                             45-49                           3        
                                             50-54                           6                 
                                             55-59                           8         
                                             60-64                          10 
                                             65-69                          11     
                                             70-74                          12      
                                             75-79                          13       
 
    TOTAL CHOLESTEROL  20-39 Yr    40-49 Yr   50-59 Yr    60-69 Yr     70-79 Yr 
<160                                                0              0               0                0                0 
169-199                                           4              3               2                 1               0             
200-239                                           7              5               3                 1               0 
240-279                                           9              6               4                 2               1 
>280                                               11             8               5                 3               1  
 
 
   SMOKER                             20-39 Yr    40-49 Yr   50-59 Yr    60-69 Yr     70-79 Yr 
 
 NO                                                 0             0                   0               0               0 
 
 YES                                               8              5                  3                1               1 
 
HDL cholesterol, mg/dl                POINTS      
 
<40                                                    2                                                      
40-49                                                 1                        
50-59                                                 0   
>60                                                   -1 
 
 
Systolic blood pressure, mm Hg          If Untreated         If treated        
 
<120                                                           0                          0  
120-129                                                      0                          1          
130-139                                                      1                          2 
140-159                                                      1                          2     
≥160                                                           2                          3   
 
  
Adding up the points  
 
Age_________________________________________________ 
T.Cholestorol___________________________________________ 
HDL-C_______________________________________________ 
Blood Pressure_________________________________________ 
Smoker_______________________________________________ 
Total Points___________________________________________ 
 
 
 
 
Point Total        10-Year Risk                Point Total                    10-Year Risk 
      <0                      <1%                              11                                  8% 
        0                        1%                              12                                 10% 
        1                        1%                              13                                 12% 
        2                        1%                              14                                 16% 
        3                        1%                              15                                  20% 
        4                        1%                              16                                  25% 
        5                        2%                             ≥17                               ≥30% 
        6                        2% 
        7                        3% 
        8                        4% 
        9                        5% 
       10                       6% 
 
ANNEXURE-2 
 
Estimate of 10-Year CHD Risk for women (Framingham Point Scores) 
 
                                         AGE,Yr                    POINTS 
                                             20–34                       -7 
                                             35–39                       -3 
                                             40–44                        0 
                                             45–49                        3 
                                             50–54                        6 
                                             55–59                        8 
                                             60–64                      10 
                                             65–69                      12 
                                             70–74                      14 
                                             75–79                      16 
 
 
 T CHOLESTEROL  20-39 Yr    40-49 Yr   50-59 Yr    60-69 Yr     70-79 Yr 
<160                              0                  0               0              0               0 
160–199                        4                   3              2              1               1 
200–239                        8                   6              4              2               1 
240–279                       11                  8              5              3               2 
>280                            13                 10              7              4               2 
 
 
   SMOKER                             20-39 Yr    40-49 Yr   50-59 Yr    60-69 Yr     70-79 Yr 
 
 NO                                             0                   0             0                 0                0 
 
 YES                                            9                   7            4                 2                 1 
 
HDL cholestorol, mg/dl                POINTS      
 
<40                                                    2                                                      
40-49                                                 1                        
50-59                                                 0   
>60                                                   -1 
 
 
Systolic blood pressure, mm Hg          If Untreated         If treated        
 
<120                                                           0                          0  
120-129                                                      1                          3          
130-139                                                      2                          4 
140-159                                                      3                          5     
≥160                                                           4                          6   
  
Adding up the points  
 
Age_________________________________________________ 
T.Cholestorol___________________________________________ 
HDL-C_______________________________________________ 
Blood Pressure_________________________________________ 
Smoker_______________________________________________ 
Total Points___________________________________________ 
 
 
 
 
Point Total        10-Year Risk                Point Total                    10-Year Risk 
 
<9                            <1%                             20                                 11% 
 9                               1%                              21                                 14% 
10                              1%                              22                                 17% 
11                              1%                              23                                 22% 
12                              1%                              24                                 27% 
13                              2%                            ≥25                               ≥30% 
14                              2% 
15                              3% 
16                              4% 
17                              5% 
18                              6% 
19                              8% 
 
s.no NAME  AGE   SEX MHC NO MARI P/H CAD P/H DM P/H HTN F/Hprechd H/Oexer H/Osmok 
1 thangavelu 50 1 1950 2 0 0 0 0 0 1 
2 rathinam 57 1 1953 2 0 0 0 0 0 0 
3 masthana 55 2 2320 2 0 0 0 0 0 0 
4 Kaniamal 56 2 2330 2 0 0 0 0 0 0 
5 murugesa 45 1 2361 2 0 0 0 0 0 2 
6 Ansari 63 1 2350 2 0 0 0 0 0 2 
7 ranjitham 57 2 2400 2 0 0 0 0 0 0 
8 rajendran 46 1 2410 2 0 0 0 0 0 0 
9 badusha 45 1 2430 2 0 0 0 0 0 1 
10 kanniapan 59 1 2429 2 0 0 0 0 0 0 
11 inbavalli 55 2 2431 2 0 0 0 0 0 0 
12 subramani 55 1 2446 2 0 0 0 0 0 0 
13 veerapathr 60 1 2462 2 0 0 0 0 0 1 
14 ashraf 45 1 2475 2 0 0 0 0 0 0 
15 abdul kar 45 1 2491 2 0 0 0 0 0 1 
16 gnanamoo 55 1 2535 2 0 0 0 0 0 0 
17 Jamuna 65 2 2536 2 0 0 0 0 0 0 
18 jeyachand 50 1 2544 2 0 0 0 3 0 1 
19 bose 56 1 2540 2 0 0 0 0 0 0 
20 suseela 55 2 2559 2 0 0 0 0 0 0 
21 chandra 60 2 2564 2 0 0 0 0 0 0 
22 ravi 48 1 2566 2 0 0 0 0 0 1 
23 bala 65 1 2562 2 0 0 0 0 0 1 
24 saroja 55 2 2563 2 0 0 0 0 0 0 
25 amaravaty 55 2 2584 2 0 0 0 0 0 0 
26 jeyaraj 45 1 2585 2 0 0 0 0 0 0 
27 karunakar 48 1 2596 2 0 0 0 0 0 1 
28 meena 56 2 2588 2 0 0 0 1 0 0 
29 selvaraj 62 1 2594 2 0 0 0 0 0 0 
30 pushpa 80 2 2596 3 0 0 0 0 0 0 
31 neelavaty 55 2 2601 2 0 0 0 0 0 0 
32 ranganath 62 1 2603 2 0 0 0 0 0 1 
33 muniamal 55 2 2605 2 0 0 0 0 0 0 
34 prema 55 2 2658 2 0 0 0 0 0 0 
35 Dasaratha 45 1 2660 2 0 0 0 0 0 2 
36 abdul jaba 54 1 2661 2 0 0 0 0 0 0 
37 patchiapa 65 1 2683 2 0 0 0 0 0 1 
38 nathan 45 1 2618 2 0 0 0 0 0 0 
39 saroja 58 2 2706 2 0 0 0 0 0 0 
40 chandra 60 1 2709 2 0 0 0 0 0 0 
41 sowdham 55 2 2710 2 0 0 0 0 0 0 
42 arumugam 49 1 2737 2 0 0 0 0 0 1 
43 jeyaraman 55 1 2735 2 0 0 0 0 0 1 
44 Krishnan 49 1 2736 2 0 0 0 0 0 1 
45 vaduvamb 60 2 2721 2 0 0 0 0 0 0 
46 thiyagaraj 46 1 2734 2 0 0 0 0 0 1 
47 baktha 60 1 2738 2 0 0 0 0 0 1 
48 prema 56 2 2760 2 0 0 0 0 0 0 
49 rajan 46 1 2761 2 0 0 0 0 0 1 
50 hema 55 2 2766 2 0 0 0 0 0 0 
 
 s.no NAME  AGE   SEX MHC NO MARI P/H CAD P/H DM P/H HTN F/Hprechd H/Oexer H/Osmok 
51 gandimath 60 2 2763 2 0 0 0 0 0 0 
52 selvam 46 1 2762 2 0 0 0 0 0 0 
53 maria 56 2 2768 2 0 0 0 0 0 0 
54 nageen 51 1 2785 2 0 0 0 0 0 1 
55 jeyalaksmi 64 2 2792 2 0 0 0 0 0 0 
56 jabbar 45 1 2833 2 0 0 0 0 0 0 
57 ramalingam 46 1 2847 2 0 0 0 0 0 0 
58 anbalagan 62 1 2835 2 0 0 0 0 0 1 
59 rani 59 2 2830 2 0 0 0 0 0 0 
60 thomas 58 1 2858 2 0 0 0 0 0 0 
61 lily rani 55 2 2874 2 0 0 0 0 0 0 
62 kanthamal 55 2 2875 2 0 0 0 0 0 0 
63 murali 45 1 2872 2 0 0 0 0 0 0 
64 mustafa 46 1 2863 2 0 0 0 0 0 0 
65 ahmed  58 1 2862 2 0 0 0 0 0 0 
66 durairaj 45 1 2864 2 0 0 0 0 0 0 
67 udaykumr 55 1 2865 2 0 0 0 1 0 0 
68 PRASAD 54 1 2872 2 0 0 0 0 0 1 
69 komala 65 2 2899 2 0 0 0 0 0 0 
70 kuppusami 62 1 2892 2 0 0 0 0 0 1 
71 mokamal 55 2 2904 2 0 0 0 0 0 0 
72 antoniamal 55 2 2911 2 0 0 0 0 0 0 
73 madhav 45 1 2912 2 0 0 0 0 0 0 
74 kumaran 46 1 2918 2 0 0 0 0 0 0 
75 narayan 45 1 2919 2 0 0 0 0 0 1 
76 roger 46 1 2920 2 0 0 0 0 0 1 
77 anippa 51 1 2922 2 0 0 0 0 0 0 
78 baskaran 45 1 2924 2 0 0 0 0 0 0 
79 jaikumar 45 1 2930 2 0 0 0 0 0 1 
80 thangavelu 56 1 2932 2 0 0 0 0 0 0 
81 subramani 47 1 2930 2 0 0 0 0 0 1 
82 thirunavu 45 1 2921 2 0 0 0 0 0 2 
83 chellaperu 49 1 2933 2 0 0 0 0 0 1 
84 sivaji 51 1 2934 2 0 0 0 0 0 0 
85 poogavnm 60 1 2923 2 0 0 0 0 0 2 
86 abibullah 68 1 2900 2 0 0 0 0 0 0 
87 ramakrisna 45 1 2902 2 0 0 0 0 0 0 
88 periasamy 46 1 2901 2 0 0 0 0 0 0 
89 arunachal 56 1 2903 2 0 0 0 0 0 1 
90 venkataiha 61 1 2904 2 0 0 0 0 0 1 
91 dharmlingam 45 1 2906 2 0 0 0 0 0 0 
92 jeychandr 49 1 2942 2 0 0 0 0 0 0 
93 manorama 56 2 2936 2 0 0 0 0 0 0 
94 sekar 45 1 2960 2 0 0 0 0 1 0 
95 govindan 57 1 2961 2 0 0 0 0 0 2 
96 raja 45 1 2935 2 0 0 0 0 0 1 
97 gunasekar 47 1 2937 2 0 0 0 0 0 1 
98 sankreswari 59 2 2938 2 0 0 0 1,2 0 0 
99 thangal 65 1 2943 2 0 0 0 0 0 0 
100 vijaybala 55 2 2945 2 0 0 0 1 0 0 
 
s.no NAME  AGE   SEX MHC NO MARI P/H CAD P/H DM P/H HTN F/Hprechd H/Oexer H/Osmok 
101 ahmed  56 1 620 2 0 0 0 0 0 1 
102 ahmed jan 68 1 630 2 0 0 0 0 0 1 
103 allimuthu 46 1 117 2 0 0 0 0 0 1 
104 andal 64 2 302 3 0 0 0 0 0 0 
105 annaporni 58 2 294 2 0 0 0 0 0 0 
106 babu 45 1 613 2 0 0 0 0 0 1 
107 baby 55 2 451 2 0 0 0 0 0 0 
108 balakrisnan 52 1 561 2 0 0 0 0 0 0 
109 chandrasekr 63 1 516 2 0 0 0 0 0 1 
110 chinasamy 67 1 493 2 0 0 0 0 0 1 
111 david 75 1 265 2 0 0 0 0 0 0 
112 dhanalaxmi 71 2 390 2 0 0 0 0 0 0 
113 dillibabu 50 1 154 2 0 0 0 0 0 1 
114 egavalli 55 2 540 2 0 0 0 0 0 0 
115 farook 55 1 285 2 0 0 0 0 0 1 
116 goovardan 53 1 565 2 0 0 0 0 0 0 
117 govindamal 56 2 1917 2 0 0 0 0 0 0 
118 govindan 55 1 25671 2 0 0 0 0 0 1 
119 gowri 56 2 683 2 0 0 0 0 0 0 
120 inbavalli 57 2 544 2 0 0 0 0 0 0 
121 jamuna 55 2 589 2 0 0 0 0 0 0 
122 jarina 57 2 660 2 0 0 0 0 0 0 
123 jayalaxmi 60 2 548 2 0 0 0 0 0 0 
124 jeyalaksmi 62 2 195 2 0 0 0 0 0 0 
125 kaliappan 56 1 438 2 0 0 0 0 0 0 
126 kantha 73 2 464 2 0 0 0 0 0 0 
127 kasinathan 70 1 489 2 0 0 0 0 0 0 
128 kokilam 56 2 376 2 0 0 0 0 0 0 
129 kumari 55 2 693 2 0 0 0 0 0 0 
130 kupammal 56 2 223 2 0 0 0 0 0 0 
131 manikam 78 1 553 3 0 0 0 0 0 0 
132 marianayagam 45 1 173 2 0 0 0 0 1 0 
133 mathew 56 1 23224 2 0 0 0 0 1 1 
134 meenakshi 60 2 399 2 0 0 0 0 0 0 
135 muniamal 56 2 312 2 0 0 0 0 0 0 
136 murugandi 48 1 39612 1 0 0 0 0 0 0 
137 padma 55 2 410 2 0 0 0 0 0 0 
138 padmavathy 56 2 184 2 0 0 0 0 0 0 
139 panjavarnam 62 2 520 2 0 0 0 0 0 0 
140 paramasivam 46 1 229 2 0 0 0 0 0 0 
141 patchiamal 58 2 619 2 0 0 0 0 0 0 
142 patchiapan 71 1 391 2 0 0 0 1 0 0 
143 poosam 55 2 654 2 0 0 0 0 0 0 
144 pushpa 56 2 618 2 0 0 0 0 0 0 
145 rajakannu 53 1 24313 2 0 0 0 0 0 0 
146 rajamani 48 1 404 2 0 0 0 0 0 0 
147 ramayee 56 2 216 2 0 0 0 0 0 0 
148 ravishankar 45 1 453 2 0 0 0 0 0 0 
149 renuka 58 2 470 2 0 0 0 0 0 0 
150 sakuntala 62 2 288 2 0 0 0 0 0 0 
 
 s.no NAME  AGE   SEX MHC NO MARI P/H CAD P/H DM P/H HTN F/Hprechd H/Oexer H/Osmok 
151 alikhan 45 1 356 2 0 0 0 0 0 0 
152 balasubramani 46 1 452 2 0 0 0 0 0 1 
153 dinesh 46 1 450 2 0 0 0 0 0 0 
154 ravi 47 1 456 2 0 0 0 0 0 1 
155 narayan 45 1 567 2 0 0 0 0 0 1 
156 krishnan 55 1 555 2 0 0 0 0 0 0 
157 babu 45 1 568 2 0 0 0 0 0 1 
158 chandra 55 2 510 2 0 0 0 0 0 0 
159 muthu 50 1 579 2 0 0 0 0 0 0 
160 meenatchi 60 1 580 2 0 0 0 0 1 0 
161 trevor 56 1 581 2 0 0 0 1 1 2 
162 kutalachangu 55 1 604 2 0 0 0 0 0 0 
163 vedachalam 45 1 630 2 0 0 0 0 0 1 
164 samutrapandian 45 1 616 2 0 0 0 2 0 0 
165 chandrasekr 46 1 626 2 0 0 0 0 0 0 
166 pakkirisami 48 1 636 2 0 0 0 0 0 1 
167 vasu 49 1 635 2 0 0 0 0 0 1 
168 boopathy 65 2 648 2 0 0 0 0 0 0 
169 anbu 57 1 649 2 0 0 0 0 0 2 
170 ravindran 45 1 650 2 0 0 0 0 0 0 
171 jeevanandam 45 1 651 2 0 0 0 0 0 0 
172 sargurudas 58 1 655 2 0 0 0 0 0 0 
173 aliakbar 48 1 654 2 0 0 0 0 0 1 
174 kumari 56 2 657 2 0 0 0 0 0 0 
175 indirani 55 2 652 2 0 0 0 0 0 0 
176 sudamani 55 1 687 2 0 0 0 0 0 0 
177 shenbagavalli 55 2 658 2 0 0 0 0 0 0 
178 anandan 45 1 660 2 0 0 0 0 0 0 
179 munikrisnan 58 1 662 2 0 0 0 0 0 0 
180 rani 55 2 664 2 0 0 0 0 0 0 
181 mahendran 45 1 665 2 0 0 0 0 0 0 
182 fatimabee 56 2 667 2 0 0 0 0 0 0 
183 sankaran 45 1 669 2 0 0 0 0 0 0 
184 lakshman 51 1 671 2 0 0 0 0 0 1 
185 ajeedadoss 45 1 673 2 0 0 0 0 0 2 
186 vijaya 56 2 675 2 0 0 0 0 0 0 
187 diilibabu 69 1 677 2 0 0 0 0 0 1 
188 saraswathy 58 2 688 2 0 0 0 0 0 0 
189 sarojini 55 2 689 2 0 0 0 0 0 0 
190 shanthi 56 2 690 2 0 0 0 0 0 0 
191 sivagami 56 2 691 2 0 0 0 0 0 0 
192 subbiah 62 1 692 2 0 0 0 0 0 1 
193 subramani 45 1 693 2 0 0 0 0 0 1 
194 kabali 48 1 694 2 0 0 0 0 0 0 
195 sriram 46 1 695 2 0 0 0 0 0 1 
196 sundaram 55 1 697 2 0 0 0 0 0 0 
197 krishnan 50 1 698 2 0 0 0 0 0 0 
198 valli 58 2 699 2 0 0 0 0 0 0 
199 sekar 45 1 700 2 0 0 0 0 0 2 
200 vasanti 58 2 702 2 0 0 0 0 0 0 
 
s.no BPAv sys BPAv dias BMI Waist circ WHR HR U albumin U sugar FBS PPBS B urea 
1 120 80 22 85 1.1 74 0 1 217 415 16 
2 120 80 25.4 78 0.9 82 0 0 83 102 26 
3 180 100 22.5 91 0.88 78 0 0 92 112 23 
4 130 80 20 75 0.8 76 0 0 90 120 22 
5 130 80 19.2 76 0.9 75 0 0 67 98 15 
6 140 90 20.8 80 0.9 78 0 0 63 111 18 
7 110 80 17 65 0.76 74 0 0 77 89 18 
8 110 80 18.5 72.5 0.9 76 0 0 50 74 18 
9 120 80 16.8 85 0.9 72 0 0 99 135 25 
10 140 100 21.75 90 0.96 76 0 0 116 132 25 
11 140 90 30.4 91.5 0.8 74 0 0 110 149 33 
12 130 80 29.2 101.5 1 78 0 0 122 173 16 
13 130 80 13.75 67.5 0.8 80 0 0 88 134 18 
14 120 80 21.2 80.5 0.9 78 0 0 72 96 22 
15 110 80 17.3 75 0.9 73 0 0 97 117 16 
16 120 80 17 65.5 0.8 78 0 0 112 150 26 
17 190 100 22.4 88.5 0.9 78 0 0 67 94 53 
18 110 80 21.2 78.5 0.9 76 0 0 105 149 28 
19 130 80 21.2 81.5 0.85 74 0 0 92 149 33 
20 120 80 19.5 74 0.8 72 0 0 86 105 20 
21 130 80 24.4 89.5 0.9 74 0 0 78 125 27 
22 120 80 21.2 82.5 0.9 72 0 0 74 83 19 
23 120 80 21.1 83.5 0.9 74 1 0 96 189 16 
24 130 80 33.2 108 0.8 76 0 0 76 184 20 
25 140 90 20.5 74.5 0.8 72 0 0 70 131 20 
26 120 80 25.2 93 1 76 0 0 53 72 13 
27 130 80 18.75 75.5 0.9 74 0 0 76 117 20 
28 150 90 24.8 93 0.9 78 0 0 79 120 21 
29 90 60 22.6 88.5 0.97 72 0 0 78 112 21 
30 150 90 15.2 62.5 0.8 74 0 0 76 118 21 
31 170 90 25.2 86.5 0.8 72 0 0 86 136 12 
32 130 90 20.3 85.5 0.9 74 0 0 111 242 15 
33 140 90 19.6 73.5 0.8 72 0 2 125 225 26 
34 130 80 29.2 87.5 0.8 76 0 0 117 145 20 
35 130 80 18 91.5 1 72 0 0 103 145 22 
36 120 80 17 66 0.84 76 0 0 61 113 26 
37 140 90 22.7 89 0.9 74 0 1 148 262 22 
38 150 100 29.6 109.5 1 72 0 2 159 316 20 
39 140 90 30.9 82.5 0.74 74 0 2 176 217 18 
40 130 90 27.5 97 0.9 72 0 0 90 120 18 
41 120 80 25.3 79 0.76 76 0 0 80 98 19 
42 140 80 26.9 67 0.8 71 0 0 90 102 24 
43 110 70 17.8 71 0.85 74 0 0 102 173 21 
44 130 90 24.2 89 0.9 76 0 2 173 388 32 
45 120 80 13.3 63 0.84 72 0 0 80 102 23 
46 130 80 29.6 99.5 0.95 76 0 0 82 146 13 
47 120 80 25.3 97 1 71 0 0 56 72 12 
48 170 90 28.7 95 0.9 76 0 0 76 96 12 
49 110 80 24 94.5 0.98 72 0 0 74 112 15 
50 180 120 27.1 91.5 0.9 74 0 0 84 94 23 
 
 s.no BPAv sys BPAv dias BMI Waist circ WHR HR U albumin U sugar FBS PPBS B urea 
51 150 90 23.2 82 0.85 71 0 0 72 116 18 
52 110 70 20.75 84 0.95 74 0 0 76 123 25 
53 100 60 15 55 0.74 72 0 0 86 138 20 
54 110 70 18 69.5 0.87 70 0 0 86 174 18 
55 190 110 35.6 104 0.9 70 0 0 86 138 24 
56 110 80 21.4 84.5 0.94 75 0 0 81 98 22 
57 110 80 14.8 58 0.8 72 0 0 84 97 23 
58 120 80 21.6 88.5 0.97 72 0 0 96 154 24 
59 120 80 23 79 0.85 71 0 0 99 119 15 
60 150 90 24.2 84 0.88 70 0 0 125 186 24 
61 150 100 29.3 90.5 0.84 70 0 0 103 182 17 
62 110 80 23.1 83 0.88 70 0 0 110 230 21 
63 130 80 21.1 79 0.9 70 0 0 102 166 14 
64 130 90 22.9 90 0.94 72 0 0 99 120 23 
65 110 80 30 105 0.9 74 0 0 115 169 23 
66 130 80 26.3 84.5 0.8 70 0 0 98 139 22 
67 140 90 25.2 87 0.9 72 0 0 104 114 25 
68 110 80 26.4 93 0.96 70 0 0 88 112 22 
69 160 90 26.6 90.5 0.84 72 0 0 126 197 25 
70 130 80 30 97.5 0.93 70 0 2 112 370 17 
71 130 80 27.77 90 0.88 72 0 0 112 123 13 
72 130 80 18.7 74 0.88 74 0 0 71 86 29 
73 150 100 28 100 0.96 70 0 0 99 133 19 
74 120 80 25.22 84.5 0.9 72 0 0 96 110 20 
75 140 100 22.26 82 0.95 70 0 0 104 140 16 
76 140 90 26 86 0.85 72 0 0 72 164 22 
77 150 100 26.9 97 0.96 74 0 0 105 145 25 
78 160 90 26.6 96 1.1 72 0 0 108 144 25 
79 140 90 30.2 101 0.97 70 0 2 161 282 14 
80 110 80 30.1 101 0.93 72 0 0 102 144 19 
81 140 90 24.5 85.5 0.95 70 0 0 90 120 26 
82 130 80 27.7 86 0.9 72 0 0 76 110 28 
83 120 80 22.2 89.5 0.93 72 0 0 80 120 17 
84 130 80 21.1 84 0.91 70 0 0 78 126 19 
85 150 90 16.8 71 0.87 74 0 0 76 118 15 
86 160 90 23.54 96.5 0.96 76 0 0 113 147 14 
87 130 80 26.8 102.5 1.01 72 0 0 109 160 16 
88 120 80 22.1 86 0.95 74 0 0 101 225 17 
89 120 80 22.35 85 0.98 72 0 0 97 179 18 
90 110 80 21.9 87 0.97 70 0 0 84 168 34 
91 110 80 21.3 76.5 0.9 74 0 0 90 128 22 
92 120 80 23 84 0.96 72 0 2 134 260 18 
93 180 110 35 100 0.86 70 0 0 65 85 23 
94 120 80 26.4 98.5 0.96 74 0 0 76 102 23 
95 130 80 21.75 79.5 0.9 74 0 0 88 110 25 
96 170 110 24.2 91 0.9 72 0 2 131 228 19 
97 110 80 29.6 99 0.94 70 0 0 103 163 15 
98 130 80 19.6 79.5 0.83 76 0 2 146 198 14 
99 130 80 29.6 97 1.1 72 0 0 110 216 18 
100 150 90 19.6 68 0.8 72 0 0 118 168 26 
 
s.no BPAv sys BPAv dias BMI Waist circ WHR HR U albumin U sugar FBS PPBS B urea 
101 160 80 22.2 80 0.9 84 0 0 60 88 34 
102 154 100 18.82 81 0.8 74 0 0 64 88 32 
103 128 86 28.65 96 1 82 1 2 190 335 20 
104 180 90 24.11 91 0.9 76 0 0 100 157 17 
105 130 80 22.93 79 0.9 80 0 0 73 118 22 
106 140 90 25.91 81 0.8 82 0 0 96 148 19 
107 167 100 30.22 83 0.8 76 0 0 92 112 34 
108 150 100 27.77 84 0.9 70 0 0 76 99 24 
109 180 110 17.54 69 0.86 84 0 0 98 110 24 
110 130 80 21.5 80 0.85 78 0 0 112 158 28 
111 190 100 22.38 68 0.8 86 0 0 105 118 23 
112 150 83 21.52 80 0.8 74 1 0 90 112 22 
113 158 100 25.14 96 0.91 78 0 0 92 136 32 
114 130 80 30.1 94 0.92 82 0 2 185 242 24 
115 150 90 23.63 84 0.9 80 0 0 58 101 16 
116 158 100 26.7 97 0.92 76 0 2 148 211 24 
117 150 90 29.04 99 0.94 82 0 0 102 153 18 
118 170 100 24.6 85 0.95 76 0 0 96 128 21 
119 150 100 29.74 99 0.93 74 0 0 82 142 21 
120 130 80 22 75 0.72 82 0 0 82 117 28 
121 130 80 22.1 78 0.76 78 0 0 64 92 24 
122 170 110 24.56 85 0.8 76 0 0 80 100 16 
123 170 90 29.28 84 0.82 74 0 0 72 116 24 
124 138 80 24.12 81 0.8 80 0 0 76 188 17 
125 168 90 22.2 78 0.8 82 0 0 98 146 34 
126 170 90 29.09 97 0.91 78 0 0 112 185 26 
127 130 80 22.67 68 0.78 74 0 0 108 146 22 
128 158 89 29.29 83 0.83 78 0 0 86 122 34 
129 180 100 25.39 84 0.9 76 0 0 89 142 19 
130 168 110 30.73 95 0.92 71 0 0 122 154 30 
131 180 100 31.6 92 0.9 78 0 0 102 146 34 
132 130 80 28.95 94 0.86 72 0 0 105 131 36 
133 180 90 30.47 96 1 78 0 0 89 124 22 
134 110 70 29.33 88 0.86 76 0 0 110 168 34 
135 130 80 28.99 72 0.76 72 0 0 82 122 22 
136 180 100 32.84 102 0.9 70 0 0 72 104 22 
137 130 80 24.23 85 0.8 82 0 0 102 145 22 
138 130 80 26.14 81 0.8 78 0 0 103 132 20 
139 140 100 30.17 98 0.91 80 0 0 94 134 36 
140 170 100 34.6 101 1.1 78 0 0 73 100 15 
141 168 100 22.18 76 0.78 82 0 0 88 102 28 
142 110 70 19.47 74 0.8 74 0 0 92 124 26 
143 130 80 20.61 81 0.8 78 0 0 60 84 28 
144 110 70 25.63 77 0.76 82 0 0 80 108 18 
145 170 90 29.66 91 0.84 74 0 0 111 126 16 
146 200 120 30.86 94 0.91 80 0 0 90 147 31 
147 130 80 24.97 83 0.9 76 0 0 124 185 30 
148 190 100 30.48 96 1.1 82 0 0 93 124 26 
149 162 100 30.22 92 0.9 72 0 0 71 86 16 
150 154 90 27.19 84 0.8 78 0 0 64 92 20 
 
 s.no BPAv sys BPAv dias BMI Waist circ WHR HR U albumin U sugar FBS PPBS B urea 
151 110 70 23.53 91 0.95 74 0 0 100 132 20 
152 110 70 18.8 79.5 0.88 72 0 0 72 106 23 
153 120 80 26.95 94 0.99 78 0 0 82 106 26 
154 100 70 24.82 94 1 76 0 0 98 136 22 
155 110 70 21.4 74.5 0.91 72 0 0 96 144 24 
156 110 70 15.1 67.5 0.96 70 0 0 74 93 22 
157 150 100 27.6 89 0.94 80 0 0 105 125 22 
158 130 80 19.4 69 0.85 82 0 1 134 168 20 
159 150 90 24.63 92.5 0.98 78 0 0 84 112 24 
160 150 90 22.8 90 0.97 78 0 0 79 110 20 
161 150 100 25.9 101 0.99 76 0 0 64 102 30 
162 140 90 21.85 85 0.89 74 0 0 74 92 28 
163 140 100 23.5 83 0.87 70 0 0 68 95 25 
164 120 80 24.5 90 0.94 72 0 0 88 150 22 
165 110 70 26.4 96.5 0.99 78 0 0 90 253 24 
166 140 100 25.48 104 0.98 74 0 2 193 305 22 
167 110 70 17.99 80 0.9 72 0 0 85 120 21 
168 180 80 21.4 73 0.78 76 0 2 101 206 19 
169 190 120 24.1 88 0.97 78 0 0 79 112 25 
170 110 70 22.69 86 0.95 76 0 0 114 141 18 
171 100 70 19.11 75 0.89 78 0 0 100 135 19 
172 132 80 23.2 97 0.93 72 0 2 250 330 17 
173 150 90 25.78 99 1.05 78 0 0 105 171 27 
174 130 80 19.48 68 0.83 82 0 0 82 116 22 
175 100 70 28.1 86 0.86 80 0 0 76 118 18 
176 130 80 21.13 90 1 78 0 0 96 148 22 
177 130 80 18.75 74 0.83 72 0 0 118 146 24 
178 110 70 21.32 82 0.92 76 0 2 99 287 19 
179 110 70 16.6 76 0.97 78 0 0 101 184 31 
180 110 70 15.83 60.5 0.77 80 0 0 82 116 18 
181 110 70 21.13 76 0.83 74 0 0 67 98 22 
182 110 70 26.29 85 0.85 78 0 0 69 112 20 
183 150 90 26.64 96 0.96 76 0 0 98 102 31 
184 160 90 22.26 88 0.98 78 0 2 148 256 17 
185 110 70 18.68 78 0.92 76 0 2 120 236 13 
186 110 70 25.45 81 0.84 80 0 2 156 248 17 
187 110 70 18.74 76 0.82 82 0 0 71 120 24 
188 160 100 22.01 84 0.92 78 0 0 128 145 35 
189 150 100 30.83 95 1.1 80 0 0 86 112 34 
190 150 100 16.63 74 0.82 78 0 0 92 110 16 
191 180 120 25.88 96 0.98 82 0 2 128 293 37 
192 190 100 32.04 101 0.9 80 0 0 92 124 29 
193 190 100 29.34 89 0.8 82 0 0 75 126 17 
194 110 70 19.28 78 0.82 78 0 0 80 114 20 
195 130 80 30.04 91 0.9 80 0 0 91 102 22 
196 168 100 25.63 80 0.8 82 0 0 71 86 15 
197 130 80 21.2 84 0.82 78 0 0 86 116 18 
198 110 70 21.35 78 0.83 84 0 0 82 118 16 
199 110 79 18.8 78 0.86 80 0 0 80 121 20 
200 160 90 32.04 101 0.9 76 0 0 86 124 23 
 
s.no S.creat TC HDL TGL VLDL LDL ECG-isch RWMA USG 10yr risk 
1 0.5 187 40 159 32 115 0 0 0 10% 
2 1 241 40 122 24 177 0 0 0 12% 
3 0.9 283 38 140 28 217 0 0 0 14% 
4 0.9 177 42 81 16 119 0 0 0 2% 
5 0.8 207 42 118 24 141 1 0 0 6% 
6 0.9 269 37 132 26 206 0 0 0 20% 
7 0.9 250 40 139 27 183 0 0 0 2% 
8 0.6 176 38 157 31 107 0 0 0 4% 
9 0.9 281 32 185 37 212 0 0 0 30% 
10 0.8 234 38 171 34 162 0 0 0 16% 
11 1 262 42 114 23 197 0 0 0 5% 
12 0.5 170 36 183 37 97 0 0 0 12% 
13 0.5 141 32 61 12 97 0 0 0 16% 
14 0.7 200 38 250 50 112 1 0 0 6% 
15 0.5 175 44 98 20 111 0 0 0 10% 
16 0.9 200 34 121 24 142 0 0 0 12% 
17 0.6 235 41 144 29 165 0 0 0 6% 
18 0.9 94 22 85 17 55 1 1 0 8% 
19 0.8 137 40 73 15 82 0 0 0 6% 
20 0.5 268 38 120 24 206 1 0 0 4% 
21 1 212 47 156 31 134 0 0 0 3% 
22 0.8 131 28 116 23 80 0 0 0 6% 
23 0.9 203 36 110 22 145 0 0 0 20% 
24 0.6 152 46 111 22 84 0 0 0 1% 
25 1 173 42 71 14 117 0 0 0 2% 
26 0.7 239 46 59 12 181 0 0 0 5% 
27 0.7 210 40 119 24 136 0 0 0 20% 
28 0.7 214 38 139 28 158 1 0 0 5% 
29 0.6 197 42 88 18 137 0 0 0 10% 
30 0.5 256 40 111 22 194 0 0 0 17% 
31 0.6 230 39 156 31 160 0 0 0 11% 
32 0.8 217 42 136 27 148 0 0 0 16% 
33 0.5 138 46 75 15 77 0 0 0 1% 
34 0.7 158 36 158 16 106 0 0 0 1% 
35 0.7 250 50 289 58 142 0 0 0 6% 
36 0.8 169 46 63 13 110 0 0 0 5% 
37 0.6 253 40 100 20 193 0 0 0 25% 
38 0.8 122 39 124 26 57 1 0 0 2% 
39 0.8 210 42 94 19 149 0 0 0 4% 
40 0.8 205 40 103 21 144 0 0 0 12% 
41 0.6 192 38 100 20 134 0 0 0 2% 
42 0.8 173 45 93 20 108 0 0 0 12% 
43 1 184 42 89 18 124 0 0 0 16% 
44 1 208 36 87 17 158 1 1 0 25% 
45 0.6 115 34 74 15 66 0 0 0 2% 
46 0.8 215 36 122 25 154 0 0 0 25% 
47 1.1 281 30 131 26 225 0 0 0 25% 
48 1 248 48 163 33 167 0 0 0 6% 
49 0.9 210 28 298 60 112 0 0 0 20% 
50 1 339 40 105 21 278 0 0 0 11% 
 
 s.no S.creat TC HDL TGL VLDL LDL ECG-isch RWMA USG 10yr risk 
51 0.7 282 42 96 19 221 0 0 0 6% 
52 0.7 235 39 71 14 182 0 0 0 6% 
53 0.7 210 40 128 26 134 0 0 0 2% 
54 0.6 129 32 90 18 79 0 0 1 8% 
55 0.8 243 36 135 27 180 0 0 0 14% 
56 0.5 214 41 117 23 150 0 0 0 5% 
57 0.6 153 39 97 19 95 0 0 0 2% 
58 0.7 196 31 155 31 134 0 0 0 16% 
59 0.6 217 34 78 16 167 0 0 0 3% 
60 0.6 167 27 133 27 113 0 0 0 12% 
61 0.8 330 38 135 27 265 1 0 0 11% 
62 0.9 202 44 84 17 141 0 0 0 2% 
63 0.7 163 49 107 21 93 0 0 0 4% 
64 1.1 311 33 151 30 248 0 0 0 16% 
65 0.9 250 28 100 20 202 1 1 0 16% 
66 0.6 155 40 107 21 94 0 0 0 4% 
67 0.8 230 32 174 35 163 0 0 0 16% 
68 1.1 143 34 120 24 85 0 0 1 8% 
69 0.8 191 36 111 22 133 0 0 1 8% 
70 0.6 188 38 96 19 131 0 0 0 20% 
71 0.5 326 41 153 51 234 0 0 0 6% 
72 0.6 211 53 79 15 143 0 0 0 2% 
73 0.8 244 43 86 17 184 0 0 0 8% 
74 0.6 175 38 81 16 121 0 0 0 4% 
75 0.8 151 45 91 18 88 0 0 0 12% 
76 0.9 259 36 151 30 193 0 0 0 30% 
77 0.9 174 32 231 46 96 0 0 0 10% 
78 1 206 32 304 61 113 0 0 0 10% 
79 0.8 210 40 202 41 129 0 0 0 25% 
80 1 195 39 154 31 125 0 0 0 10% 
81 1 255 38 154 31 186 0 0 0 25% 
82 1 256 40 120 24 192 0 0 0 8% 
83 0.8 211 36 115 23 152 0 0 0 20% 
84 0.9 253 32 206 41 180 0 0 1 12% 
85 0.7 153 34 114 23 96 0 0 0 16% 
86 0.8 225 39 219 44 142 0 0 0 30% 
87 0.8 308 40 189 38 230 1 0 0 12% 
88 0.8 241 32 395 79 130 0 0 0 8% 
89 0.9 292 36 396 79 177 0 0 0 30% 
90 1.2 188 30 200 40 118 0 0 0 16% 
91 0.8 237 36 154 31 170 0 0 0 6% 
92 0.7 317 42 176 35 230 0 0 0 10% 
93 0.9 216 40 165 33 139 0 0 0 5% 
94 1 163 38 124 25 100 0 0 0 4% 
95 0.9 174 40 131 26 108 0 0 0 10% 
96 0.8 217 35 248 50 132 0 0 0 30% 
97 0.7 205 38 182 36 131 0 0 1 20% 
98 0.8 155 44 182 36 75 0 0 0 1% 
99 0.8 326 32 144 29 265 0 0 0 30% 
100 0.9 215 42 120 24 149 0 0 0 6% 
 
s.no S.creat TC HDL TGL VLDL LDL ECG-isch RWMA USG 10yr risk 
101 1.1 160 40 121 24 96 0 0 0 25% 
102 1.3 184 41 126 25 118 0 0 0 25% 
103 1.1 230 24 162 32 174 0 0 0 20% 
104 0.5 168 35 142 28 105 0 0 0 5% 
105 1.2 149 38 89 18 93 0 0 0 2% 
106 0.8 162 30 122 24 108 0 0 0 5% 
107 0.9 152 36 112 22 94 0 0 0 2% 
108 0.8 168 38 101 20 110 0 0 0 8% 
109 0.9 164 48 120 24 92 0 0 0 16% 
110 0.9 176 32 124 24 120 0 0 0 25% 
111 1.2 162 44 119 24 94 0 0 0 25% 
112 1 174 36 128 26 112 0 0 0 11% 
113 1 186 28 142 28 130 0 0 0 16% 
114 0.9 168 45 124 25 98 0 0 0 2% 
115 0.9 209 41 99 20 148 0 0 0 25% 
116 1.1 162 39 102 20 103 0 0 0 6% 
117 0.9 240 21 160 32 187 0 0 0 6% 
118 1 202 29 164 33 140 0 0 0 30% 
119 1 162 34 132 26 102 0 0 0 3% 
120 0.7 172 51 112 22 99 0 0 0 1% 
121 0.9 168 37 108 22 109 0 0 0 2% 
122 0.8 144 44 103 21 79 0 0 0 2% 
123 0.8 136 40 107 21 75 0 0 0 3% 
124 1.1 185 58 105 21 106 0 0 0 2% 
125 0.8 142 39 92 18 85 0 0 0 10% 
126 0.9 202 32 145 29 141 0 0 0 14% 
127 1 149 46 102 20 83 0 0 0 16% 
128 0.9 165 42 111 22 101 0 0 0 2% 
129 0.9 168 30 142 28 110 0 0 0 4% 
130 0.9 241 32 168 34 175 0 0 0 8% 
131 1 156 34 96 19 103 0 0 0 30% 
132 1 178 49 112 22 107 0 0 0 4% 
133 0.9 242 34 156 31 177 0 0 0 30% 
134 1 182 42 104 21 119 0 0 0 1% 
135 0.9 175 40 152 30 105 0 0 0 2% 
136 1.2 254 32 198 40 182 0 0 0 12% 
137 1 186 34 124 25 127 0 0 0 2% 
138 0.8 142 45 102 20 77 0 0 0 1% 
139 1.2 163 44 158 32 87 0 0 0 3% 
140 0.8 262 33 185 37 192 0 0 0 12% 
141 1.1 184 40 124 25 119 0 0 0 3% 
142 1 158 35 122 24 99 0 0 0 16% 
143 0.6 172 28 136 27 117 0 0 0 2% 
144 0.8 130 39 127 25 66 0 0 0 1% 
145 1 231 34 168 34 163 0 0 0 12% 
146 1.1 194 30 156 31 133 0 0 0 6% 
147 1.2 168 42 102 20 106 0 0 0 2% 
148 1 201 35 142 28 138 0 0 0 10% 
149 0.8 188 28 135 27 133 0 0 0 4% 
150 1 239 32 138 28 179 0 0 0 5% 
 
 s.no S.creat TC HDL TGL VLDL LDL ECG-isch RWMA USG 10yr risk 
151 0.8 169 44 98 20 105 0 0 0 3% 
152 0.6 198 43 95 19 136 0 0 0 10% 
153 1 212 32 224 45 135 0 0 0 6% 
154 0.8 267 42 186 37 188 0 0 0 20% 
155 0.8 208 38 154 31 139 0 0 0 20% 
156 0.7 198 45 124 25 128 0 0 0 8% 
157 0.8 211 33 185 37 141 0 0 0 25% 
158 0.7 226 40 163 33 153 0 0 0 3% 
159 0.8 172 42 101 20 110 0 0 0 6% 
160 0.7 198 44 101 20 134 0 0 0 12% 
161 0.9 205 38 174 35 132 0 0 0 16% 
162 1.1 221 41 107 21 159 0 0 0 12% 
163 0.9 143 46 95 19 78 0 0 0 6% 
164 0.9 202 39 146 29 134 0 0 0 8% 
165 0.8 315 31 123 25 259 0 0 2 12% 
166 0.8 291 35 157 31 225 0 0 0 30% 
167 0.5 201 30 218 44 127 0 0 0 20% 
168 0.7 193 39 121 24 130 0 0 0 8% 
169 0.9 210 42 107 21 147 0 0 0 20% 
170 0.7 192 37 149 30 125 0 0 0 4% 
171 0.7 134 40 83 17 77 0 0 0 1% 
172 0.9 330 38 154 31 261 0 0 0 25% 
173 0.7 286 31 252 50 205 0 0 0 30% 
174 0.8 220 39 141 28 153 0 0 0 4% 
175 0.7 213 45 107 21 147 0 0 0 2% 
176 0.7 248 42 143 29 177 0 0 0 16% 
177 0.8 324 41 279 56 227 0 0 0 6% 
178 0.8 340 40 200 40 260 0 0 0 10% 
179 1.1 120 30 81 16 74 0 0 0 6% 
180 0.8 415 30 274 55 330 0 0 0 5% 
181 0.8 140 30 105 21 89 0 0 0 2% 
182 0.7 160 32 110 22 106 0 0 0 1% 
183 0.9 265 36 185 37 192 0 0 0 10% 
184 1.1 314 36 207 41 237 0 0 0 30% 
185 1 181 42 164 33 100 0 0 0 3% 
186 0.8 236 40 187 35 161 0 0 0 2% 
187 0.9 114 48 47 9 57 0 0 0 12% 
188 0.8 204 45 112 22 137 0 0 0 5% 
189 0.9 216 21 161 32 163 0 0 0 5% 
190 1.2 148 32 102 20 96 0 0 0 2% 
191 1.2 210 45 176 35 130 0 0 0 5% 
192 0.9 273 34 173 35 204 0 0 0 30% 
193 0.9 162 42 102 20 100 0 0 0 16% 
194 0.6 200 38 140 28 134 0 0 0 5% 
195 0.8 180 32 145 29 129 0 0 0 16% 
196 0.8 188 28 135 27 133 0 0 0 16% 
197 0.8 193 39 140 28 126 0 0 0 6% 
198 1 146 34 120 24 88 0 0 0 1% 
199 0.9 143 34 120 24 85 0 0 0 2% 
200 1.2 163 37 148 30 96 0 0 0 4% 
 
                                     
                                                    LEGEND TO MASTER CHART 
 
 
 
 
             
         Sex 
 
1=Male,2=Female 
      Marital Status 1=Single, 2=Married,3=Widowed 
 
      Past H/O CHD  1=Yes, 0=No 
 
      Past H/O Diabetes Mellitus  1=Yes,0=No 
      Past H/O Hypertension 1=Yes,0=No 
      Family H/O Premature CHD 0=None,1=Father,2=Mother,3=Brother 
4=Sister 
      H/O Exercise 1=Yes,0=No 
      H/O Smoking 1=Yes,0=No 
      Urine Albumin 0=None,1=1+,2=2+,3=3+,4=4+ 
      Urine Sugar 0=None,1=1+,2=2+,3=3+,4=4+ 
      ECG-Ischemia 1=Yes,0=No 
      ECHO-RWMA 1=Yes,0=No 
      USG-Evidence of nephropathy 1=Yes,0=No 
 
 
LIST OF ABBREVIATIONS : 
 
        CHD : Coronary heart disease 
 
        NCEP-ATPIII- National cholesterol education program-Adult Treatment Panel III 
        
        AHA/NHLBI-American Heart association/National Heart, Lung,Brain Institute   
 
        T.C- Total Cholesterol 
       
        H.D.L- High density lipoprotein cholesterol 
 
        LDL-Low density lipoprotein cholesterol 
            
        TGL-Triglyceride, WHR-Waist Hip ratio, IFG-Impaired fasting glucose 
 
        IGT-Impaired glucose tolerance , D.M-Diabetes Mellitus 
        
        HTN-Hypertension 
 
        FRS-Framingham Risk score  
